Details of the Drug Combinations

General Information of This Drug (ID: DMCMBHA)

Drug Name
Erlotinib   DMCMBHA
Synonyms
Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-Quinazolinamine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline; 4-[(3-ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline
Indication
Disease Entry ICD 11 Status REF
Adrenal gland neoplasm N.A. Approved [1]
Adult hepatocellular carcinoma N.A. Approved [1]
Brain cancer 2A00 Approved [1]
Esophageal disorder N.A. Approved [1]
Lung cancer 2C25.0 Approved [1]
Non-small-cell lung cancer 2C25.Y Approved [2]
Pancreatic adenocarcinoma N.A. Approved [1]
Psoriasis EA90 Approved [1]
Salivary gland squamous cell carcinoma N.A. Approved [1]
Pancreatic cancer 2C10 Phase 3 [2]
Colon cancer 2B90.Z Phase 2 [2]
Ependymoma 2A00.0Y Investigative [1]
Neoplastic meningitis N.A. Investigative [1]
Neuroblastoma 2D11.2 Investigative [1]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

809 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
Cyclophosphamide + Erlotinib DCCZDGF Cyclophosphamide Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
Cyclophosphamide + Erlotinib DC2XMT0 Cyclophosphamide Breast carcinoma (Cell Line: ZR751) [4]
Dexamethasone + Erlotinib DC42MB0 Dexamethasone Adenocarcinoma (Cell Line: CAOV3) [5]
Dexamethasone + Erlotinib DC2NSDB Dexamethasone Adenocarcinoma (Cell Line: NCIH1650) [5]
Dexamethasone + Erlotinib DCY75BB Dexamethasone Adenocarcinoma (Cell Line: NCIH2122) [5]
Dexamethasone + Erlotinib DCDCQPD Dexamethasone Adenocarcinoma (Cell Line: SW-620) [5]
Dexamethasone + Erlotinib DCI2MTQ Dexamethasone Germ cell tumour (Cell Line: PA1) [5]
Doxorubicin + Erlotinib DCXLF43 Doxorubicin Adenocarcinoma (Cell Line: CAOV3) [3]
Doxorubicin + Erlotinib DC2XETV Doxorubicin Adenocarcinoma (Cell Line: NCIH2122) [3]
Doxorubicin + Erlotinib DCXKCRQ Doxorubicin Adenocarcinoma (Cell Line: NCIH23) [3]
Doxorubicin + Erlotinib DCEK41E Doxorubicin Adenocarcinoma (Cell Line: NCIH520) [3]
Doxorubicin + Erlotinib DCB8VUF Doxorubicin Adenocarcinoma (Cell Line: HT29) [3]
Doxorubicin + Erlotinib DCZWI13 Doxorubicin Adenocarcinoma (Cell Line: SW-620) [3]
Doxorubicin + Erlotinib DCDE839 Doxorubicin Amelanotic melanoma (Cell Line: A2058) [3]
Doxorubicin + Erlotinib DCDJWLC Doxorubicin Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Doxorubicin + Erlotinib DCTSRP1 Doxorubicin Malignant melanoma (Cell Line: HT144) [3]
Doxorubicin + Erlotinib DCM6Z3B Doxorubicin Malignant melanoma (Cell Line: RPMI7951) [3]
Doxorubicin + Erlotinib DCL9AAL Doxorubicin Malignant melanoma (Cell Line: UACC62) [3]
Doxorubicin + Erlotinib DCZU26H Doxorubicin Mesothelioma (Cell Line: MSTO) [3]
Doxorubicin + Erlotinib DCRLMZV Doxorubicin Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
Doxorubicin + Erlotinib DC77W5I Doxorubicin Breast carcinoma (Cell Line: OCUBM) [4]
Doxorubicin + Erlotinib DCQHT53 Doxorubicin Invasive ductal carcinoma (Cell Line: T-47D) [4]
Doxorubicin + Erlotinib DCL79LZ Doxorubicin Rectal adenocarcinoma (Cell Line: SW837) [4]
Erlotinib + Buparlisib DCB42SD Buparlisib Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [3]
Erlotinib + PD-0325901 DCFF73B PD-0325901 Adenocarcinoma (Cell Line: CAOV3) [3]
Erlotinib + PD-0325901 DCOAHGV PD-0325901 Adenocarcinoma (Cell Line: NCIH1650) [3]
Erlotinib + PD-0325901 DCQD2J4 PD-0325901 Adenocarcinoma (Cell Line: NCIH2122) [3]
Erlotinib + PD-0325901 DCNO82O PD-0325901 Adenocarcinoma (Cell Line: COLO320DM) [3]
Erlotinib + PD-0325901 DCHA3MV PD-0325901 Adenocarcinoma (Cell Line: DLD1) [3]
Erlotinib + PD-0325901 DCZNCV2 PD-0325901 Amelanotic melanoma (Cell Line: A2058) [3]
Erlotinib + PD-0325901 DCMEZXS PD-0325901 Germ cell tumour (Cell Line: PA1) [3]
Erlotinib + PD-0325901 DC7AYRW PD-0325901 Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Erlotinib + PD-0325901 DCA2WUE PD-0325901 Malignant melanoma (Cell Line: A375) [3]
Erlotinib + PD-0325901 DCSVYUE PD-0325901 Malignant melanoma (Cell Line: HT144) [3]
Erlotinib + PD-0325901 DCXRKRI PD-0325901 Malignant melanoma (Cell Line: SKMEL30) [3]
Erlotinib + PD-0325901 DCV2YIR PD-0325901 Malignant melanoma (Cell Line: UACC62) [3]
Erlotinib + PD-0325901 DCM2YFH PD-0325901 Mesothelioma (Cell Line: MSTO) [3]
Erlotinib + PD-0325901 DCRJZCE PD-0325901 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
Erlotinib + AT13387 DC48IOQ AT13387 Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [3]
Erlotinib + JQ1 DCNG14S JQ1 Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [3]
Erlotinib + Crizotinib DC57P2N Crizotinib Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [3]
Erlotinib + Panobinostat DCE3E7Y Panobinostat Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [3]
Erlotinib + RTB101 DC2IMRK RTB101 Adenocarcinoma (Cell Line: CAOV3) [3]
Erlotinib + RTB101 DC6KS73 RTB101 Adenocarcinoma (Cell Line: OVCAR3) [3]
Erlotinib + RTB101 DCQ0O95 RTB101 Adenocarcinoma (Cell Line: A427) [3]
Erlotinib + RTB101 DCXHR9O RTB101 Adenocarcinoma (Cell Line: NCIH2122) [3]
Erlotinib + RTB101 DCHYUVR RTB101 Adenocarcinoma (Cell Line: NCIH23) [3]
Erlotinib + RTB101 DCCOEML RTB101 Adenocarcinoma (Cell Line: NCIH520) [3]
Erlotinib + RTB101 DCOGT16 RTB101 Adenocarcinoma (Cell Line: COLO320DM) [3]
Erlotinib + RTB101 DC2C2Z0 RTB101 Adenocarcinoma (Cell Line: DLD1) [3]
Erlotinib + RTB101 DCDQFN6 RTB101 Adenocarcinoma (Cell Line: HT29) [3]
Erlotinib + RTB101 DCLXXKH RTB101 Amelanotic melanoma (Cell Line: A2058) [3]
Erlotinib + RTB101 DC15FZK RTB101 Germ cell tumour (Cell Line: PA1) [3]
Erlotinib + RTB101 DC6D0KD RTB101 Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Erlotinib + RTB101 DC8VFMG RTB101 Malignant melanoma (Cell Line: A375) [3]
Erlotinib + RTB101 DCQ0Q02 RTB101 Malignant melanoma (Cell Line: HT144) [3]
Erlotinib + RTB101 DCVYZI7 RTB101 Malignant melanoma (Cell Line: RPMI7951) [3]
Erlotinib + RTB101 DC95JR4 RTB101 Malignant melanoma (Cell Line: SKMEL30) [3]
Erlotinib + RTB101 DCAHKIS RTB101 Malignant melanoma (Cell Line: UACC62) [3]
Erlotinib + RTB101 DCZ4C4N RTB101 Mesothelioma (Cell Line: MSTO) [3]
Erlotinib + RTB101 DC6DU05 RTB101 Non small cell carcinoma (Cell Line: SKMES1) [3]
Erlotinib + RTB101 DC7F52W RTB101 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
Erlotinib + RTB101 DCRQRZX RTB101 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Erlotinib + RTB101 DC70IJ0 RTB101 Prostate carcinoma (Cell Line: LNCAP) [3]
Erlotinib + RTB101 DC6ED4F RTB101 Prostate carcinoma (Cell Line: VCAP) [3]
Erlotinib + SCH-900776 DCF8BZU SCH-900776 Adenocarcinoma (Cell Line: OVCAR3) [3]
Erlotinib + SCH-900776 DCTTDP0 SCH-900776 Adenocarcinoma (Cell Line: CAOV3) [3]
Erlotinib + SCH-900776 DC2XL6A SCH-900776 Adenocarcinoma (Cell Line: A427) [3]
Erlotinib + SCH-900776 DCIKKKF SCH-900776 Adenocarcinoma (Cell Line: NCIH2122) [3]
Erlotinib + SCH-900776 DCU81XR SCH-900776 Adenocarcinoma (Cell Line: NCIH23) [3]
Erlotinib + SCH-900776 DCXFE85 SCH-900776 Adenocarcinoma (Cell Line: NCIH520) [3]
Erlotinib + SCH-900776 DCKX7YD SCH-900776 Adenocarcinoma (Cell Line: COLO320DM) [3]
Erlotinib + SCH-900776 DCX7EJU SCH-900776 Adenocarcinoma (Cell Line: DLD1) [3]
Erlotinib + SCH-900776 DCKOTM9 SCH-900776 Adenocarcinoma (Cell Line: HT29) [3]
Erlotinib + SCH-900776 DCQ2UF3 SCH-900776 Adenocarcinoma (Cell Line: SW-620) [3]
Erlotinib + SCH-900776 DC9GKCF SCH-900776 Adenocarcinoma (Cell Line: HCT116) [3]
Erlotinib + SCH-900776 DCVPQTS SCH-900776 Amelanotic melanoma (Cell Line: A2058) [3]
Erlotinib + SCH-900776 DC7UZV4 SCH-900776 Germ cell tumour (Cell Line: PA1) [3]
Erlotinib + SCH-900776 DCEKLJP SCH-900776 Malignant melanoma (Cell Line: HT144) [3]
Erlotinib + SCH-900776 DCXLZSI SCH-900776 Malignant melanoma (Cell Line: RPMI7951) [3]
Erlotinib + SCH-900776 DCW6E16 SCH-900776 Malignant melanoma (Cell Line: SKMEL30) [3]
Erlotinib + SCH-900776 DCA2ZYO SCH-900776 Malignant melanoma (Cell Line: UACC62) [3]
Erlotinib + SCH-900776 DCP2AOX SCH-900776 Malignant melanoma (Cell Line: A375) [3]
Erlotinib + SCH-900776 DCXZ5EZ SCH-900776 Mesothelioma (Cell Line: MSTO) [3]
Erlotinib + SCH-900776 DCTS95G SCH-900776 Non small cell carcinoma (Cell Line: SKMES1) [3]
Erlotinib + SCH-900776 DC0OQIR SCH-900776 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
Erlotinib + SCH-900776 DCXIX79 SCH-900776 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Erlotinib + SCH-900776 DCNLBJK SCH-900776 Prostate carcinoma (Cell Line: LNCAP) [3]
Erlotinib + Alvespimycin hydrochloride DC6MF6L Alvespimycin hydrochloride Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [3]
Erlotinib + LY2835219 DC94UEB LY2835219 Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [3]
Erlotinib + 10-hydroxycamptothecin DC1X7QO 10-hydroxycamptothecin Adenocarcinoma (Cell Line: CAOV3) [3]
Erlotinib + 10-hydroxycamptothecin DCBVTYP 10-hydroxycamptothecin Adenocarcinoma (Cell Line: A427) [3]
Erlotinib + 10-hydroxycamptothecin DCG592S 10-hydroxycamptothecin Adenocarcinoma (Cell Line: NCIH1650) [3]
Erlotinib + 10-hydroxycamptothecin DCTWYSV 10-hydroxycamptothecin Adenocarcinoma (Cell Line: NCIH2122) [3]
Erlotinib + 10-hydroxycamptothecin DCOGCDV 10-hydroxycamptothecin Adenocarcinoma (Cell Line: NCIH23) [3]
Erlotinib + 10-hydroxycamptothecin DCMDS39 10-hydroxycamptothecin Adenocarcinoma (Cell Line: NCIH520) [3]
Erlotinib + 10-hydroxycamptothecin DC6HO3V 10-hydroxycamptothecin Adenocarcinoma (Cell Line: COLO320DM) [3]
Erlotinib + 10-hydroxycamptothecin DCXKO6O 10-hydroxycamptothecin Adenocarcinoma (Cell Line: DLD1) [3]
Erlotinib + 10-hydroxycamptothecin DC0IQDD 10-hydroxycamptothecin Adenocarcinoma (Cell Line: HT29) [3]
Erlotinib + 10-hydroxycamptothecin DCDDHWD 10-hydroxycamptothecin Adenocarcinoma (Cell Line: SW-620) [3]
Erlotinib + 10-hydroxycamptothecin DCFG7PH 10-hydroxycamptothecin Amelanotic melanoma (Cell Line: A2058) [3]
Erlotinib + 10-hydroxycamptothecin DCHSL6N 10-hydroxycamptothecin Germ cell tumour (Cell Line: PA1) [3]
Erlotinib + 10-hydroxycamptothecin DCZZXKZ 10-hydroxycamptothecin Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Erlotinib + 10-hydroxycamptothecin DCEFY8Y 10-hydroxycamptothecin Malignant melanoma (Cell Line: A375) [3]
Erlotinib + 10-hydroxycamptothecin DC3FKYU 10-hydroxycamptothecin Malignant melanoma (Cell Line: RPMI7951) [3]
Erlotinib + 10-hydroxycamptothecin DCRJZMI 10-hydroxycamptothecin Malignant melanoma (Cell Line: SKMEL30) [3]
Erlotinib + 10-hydroxycamptothecin DCYYXS7 10-hydroxycamptothecin Malignant melanoma (Cell Line: UACC62) [3]
Erlotinib + 10-hydroxycamptothecin DCK3F2V 10-hydroxycamptothecin Mesothelioma (Cell Line: MSTO) [3]
Erlotinib + 10-hydroxycamptothecin DCWQNS1 10-hydroxycamptothecin Non small cell carcinoma (Cell Line: SKMES1) [3]
Erlotinib + 10-hydroxycamptothecin DCSQ842 10-hydroxycamptothecin Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
Erlotinib + 10-hydroxycamptothecin DCXU8TY 10-hydroxycamptothecin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Erlotinib + 10-hydroxycamptothecin DCS0I32 10-hydroxycamptothecin Prostate carcinoma (Cell Line: VCAP) [3]
Erlotinib + SNX-2112 DC9NRVW SNX-2112 Adenocarcinoma (Cell Line: CAOV3) [3]
Erlotinib + SNX-2112 DC2FZQJ SNX-2112 Adenocarcinoma (Cell Line: OVCAR3) [3]
Erlotinib + SNX-2112 DCACMZ9 SNX-2112 Adenocarcinoma (Cell Line: A427) [3]
Erlotinib + SNX-2112 DCRK3B9 SNX-2112 Adenocarcinoma (Cell Line: NCIH1650) [3]
Erlotinib + SNX-2112 DCAAGHB SNX-2112 Adenocarcinoma (Cell Line: NCIH2122) [3]
Erlotinib + SNX-2112 DCEFHCQ SNX-2112 Adenocarcinoma (Cell Line: NCIH520) [3]
Erlotinib + SNX-2112 DCC3SVB SNX-2112 Adenocarcinoma (Cell Line: DLD1) [3]
Erlotinib + SNX-2112 DCXE2VY SNX-2112 Adenocarcinoma (Cell Line: HT29) [3]
Erlotinib + SNX-2112 DCS7SV7 SNX-2112 Adenocarcinoma (Cell Line: SW-620) [3]
Erlotinib + SNX-2112 DC7V5NC SNX-2112 Amelanotic melanoma (Cell Line: A2058) [3]
Erlotinib + SNX-2112 DC8O74J SNX-2112 Germ cell tumour (Cell Line: PA1) [3]
Erlotinib + SNX-2112 DCBLMFQ SNX-2112 Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Erlotinib + SNX-2112 DCODAF2 SNX-2112 Malignant melanoma (Cell Line: A375) [3]
Erlotinib + SNX-2112 DCABR7B SNX-2112 Malignant melanoma (Cell Line: HT144) [3]
Erlotinib + SNX-2112 DCE0P5I SNX-2112 Malignant melanoma (Cell Line: SKMEL30) [3]
Erlotinib + SNX-2112 DCPWHBW SNX-2112 Malignant melanoma (Cell Line: UACC62) [3]
Erlotinib + SNX-2112 DC96HYR SNX-2112 Mesothelioma (Cell Line: MSTO) [3]
Erlotinib + SNX-2112 DCR1YDL SNX-2112 Non small cell carcinoma (Cell Line: SKMES1) [3]
Erlotinib + SNX-2112 DC5U26J SNX-2112 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
Erlotinib + SNX-2112 DCOQ9YP SNX-2112 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Erlotinib + SNX-2112 DCLQPRW SNX-2112 Prostate carcinoma (Cell Line: VCAP) [3]
Erlotinib + Vincristine DCVY1OQ Vincristine Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [3]
Erlotinib + Ridaforolimus DCWH7NK Ridaforolimus Adenocarcinoma (Cell Line: OVCAR3) [3]
Erlotinib + Ridaforolimus DCR179M Ridaforolimus Adenocarcinoma (Cell Line: CAOV3) [3]
Erlotinib + Ridaforolimus DCV6JQ5 Ridaforolimus Adenocarcinoma (Cell Line: A427) [3]
Erlotinib + Ridaforolimus DCLTVXF Ridaforolimus Adenocarcinoma (Cell Line: NCIH1650) [3]
Erlotinib + Ridaforolimus DCA65YB Ridaforolimus Adenocarcinoma (Cell Line: NCIH2122) [3]
Erlotinib + Ridaforolimus DCC1QVD Ridaforolimus Adenocarcinoma (Cell Line: NCIH23) [3]
Erlotinib + Ridaforolimus DCJMJV6 Ridaforolimus Adenocarcinoma (Cell Line: NCIH520) [3]
Erlotinib + Ridaforolimus DC8N6CQ Ridaforolimus Adenocarcinoma (Cell Line: COLO320DM) [3]
Erlotinib + Ridaforolimus DCFRRB8 Ridaforolimus Adenocarcinoma (Cell Line: DLD1) [3]
Erlotinib + Ridaforolimus DCW7RFA Ridaforolimus Adenocarcinoma (Cell Line: HT29) [3]
Erlotinib + Ridaforolimus DCEAV2S Ridaforolimus Adenocarcinoma (Cell Line: SW-620) [3]
Erlotinib + Ridaforolimus DCB7UL1 Ridaforolimus Amelanotic melanoma (Cell Line: A2058) [3]
Erlotinib + Ridaforolimus DCN4F3B Ridaforolimus Germ cell tumour (Cell Line: PA1) [3]
Erlotinib + Ridaforolimus DCMY13N Ridaforolimus Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Erlotinib + Ridaforolimus DC1W58Z Ridaforolimus Malignant melanoma (Cell Line: HT144) [3]
Erlotinib + Ridaforolimus DC0K92Q Ridaforolimus Malignant melanoma (Cell Line: RPMI7951) [3]
Erlotinib + Ridaforolimus DCFNJJW Ridaforolimus Malignant melanoma (Cell Line: SKMEL30) [3]
Erlotinib + Ridaforolimus DCKGOOX Ridaforolimus Malignant melanoma (Cell Line: UACC62) [3]
Erlotinib + Ridaforolimus DCL77IM Ridaforolimus Malignant melanoma (Cell Line: A375) [3]
Erlotinib + Ridaforolimus DC28KEE Ridaforolimus Mesothelioma (Cell Line: MSTO) [3]
Erlotinib + Ridaforolimus DCDLBFY Ridaforolimus Non small cell carcinoma (Cell Line: SKMES1) [3]
Erlotinib + Ridaforolimus DCIP0BL Ridaforolimus Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
Erlotinib + Ridaforolimus DCBIK1Y Ridaforolimus Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Erlotinib + Ridaforolimus DC1OSCM Ridaforolimus Prostate carcinoma (Cell Line: LNCAP) [3]
Erlotinib + MK-4827 DC03QIJ MK-4827 Adenocarcinoma (Cell Line: CAOV3) [3]
Erlotinib + MK-4827 DCGH1IE MK-4827 Adenocarcinoma (Cell Line: OVCAR3) [3]
Erlotinib + MK-4827 DCJMO4P MK-4827 Adenocarcinoma (Cell Line: A427) [3]
Erlotinib + MK-4827 DCUH9VF MK-4827 Adenocarcinoma (Cell Line: NCIH2122) [3]
Erlotinib + MK-4827 DC19XR0 MK-4827 Adenocarcinoma (Cell Line: NCIH23) [3]
Erlotinib + MK-4827 DCG54VV MK-4827 Adenocarcinoma (Cell Line: NCIH520) [3]
Erlotinib + MK-4827 DC5Y81L MK-4827 Adenocarcinoma (Cell Line: COLO320DM) [3]
Erlotinib + MK-4827 DCL2ANL MK-4827 Adenocarcinoma (Cell Line: DLD1) [3]
Erlotinib + MK-4827 DCJTYT7 MK-4827 Adenocarcinoma (Cell Line: HCT116) [3]
Erlotinib + MK-4827 DC0W83Z MK-4827 Adenocarcinoma (Cell Line: HT29) [3]
Erlotinib + MK-4827 DC5FCN9 MK-4827 Adenocarcinoma (Cell Line: SW-620) [3]
Erlotinib + MK-4827 DCN9VS2 MK-4827 Amelanotic melanoma (Cell Line: A2058) [3]
Erlotinib + MK-4827 DCM6AE4 MK-4827 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
Erlotinib + MK-4827 DCH02J5 MK-4827 Germ cell tumour (Cell Line: PA1) [3]
Erlotinib + MK-4827 DC0VV6K MK-4827 Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Erlotinib + MK-4827 DCHEDY8 MK-4827 Malignant melanoma (Cell Line: A375) [3]
Erlotinib + MK-4827 DC3POQE MK-4827 Malignant melanoma (Cell Line: HT144) [3]
Erlotinib + MK-4827 DCG0M5A MK-4827 Malignant melanoma (Cell Line: RPMI7951) [3]
Erlotinib + MK-4827 DCZ8NAS MK-4827 Malignant melanoma (Cell Line: SKMEL30) [3]
Erlotinib + MK-4827 DCTFYGE MK-4827 Malignant melanoma (Cell Line: UACC62) [3]
Erlotinib + MK-4827 DC4R5XF MK-4827 Non small cell carcinoma (Cell Line: SKMES1) [3]
Erlotinib + MK-4827 DC011UA MK-4827 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
Erlotinib + MK-4827 DCVUA20 MK-4827 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Erlotinib + MK-4827 DC98K69 MK-4827 Prostate carcinoma (Cell Line: LNCAP) [3]
Erlotinib + Lomustine DCT0J3Z Lomustine Mesothelioma (Cell Line: MSTO) [3]
Erlotinib + Lomustine DCQYS1B Lomustine Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
Erlotinib + Lomustine DCL33KA Lomustine Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Erlotinib + Bortezomib DCSPRY5 Bortezomib Adenocarcinoma (Cell Line: CAOV3) [3]
Erlotinib + Bortezomib DCIMLCN Bortezomib Adenocarcinoma (Cell Line: OVCAR3) [3]
Erlotinib + Bortezomib DCCGD91 Bortezomib Adenocarcinoma (Cell Line: NCIH2122) [3]
Erlotinib + Bortezomib DCBTI3Z Bortezomib Adenocarcinoma (Cell Line: NCIH23) [3]
Erlotinib + Bortezomib DC4HGMW Bortezomib Adenocarcinoma (Cell Line: COLO320DM) [3]
Erlotinib + Bortezomib DC7D6OW Bortezomib Adenocarcinoma (Cell Line: DLD1) [3]
Erlotinib + Bortezomib DCXJF7D Bortezomib Adenocarcinoma (Cell Line: HT29) [3]
Erlotinib + Bortezomib DCSGIP0 Bortezomib Adenocarcinoma (Cell Line: SW-620) [3]
Erlotinib + Bortezomib DCAU1WL Bortezomib Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Erlotinib + Bortezomib DCLZ968 Bortezomib Malignant melanoma (Cell Line: A375) [3]
Erlotinib + Bortezomib DCGQGN3 Bortezomib Malignant melanoma (Cell Line: RPMI7951) [3]
Erlotinib + Bortezomib DC9ARZ8 Bortezomib Malignant melanoma (Cell Line: SKMEL30) [3]
Erlotinib + Bortezomib DCLK0MH Bortezomib Mesothelioma (Cell Line: MSTO) [3]
Erlotinib + Bortezomib DC39SCU Bortezomib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
Erlotinib + Bortezomib DCXGXHG Bortezomib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Erlotinib + Bortezomib DC322MJ Bortezomib Prostate carcinoma (Cell Line: VCAP) [3]
Erlotinib + GSK525762 DC3HVR5 GSK525762 Adenocarcinoma (Cell Line: NCIH1650) [3]
Erlotinib + GSK525762 DCBYE5C GSK525762 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
Erlotinib + GSK525762 DCDRG5H GSK525762 Mesothelioma (Cell Line: MSTO) [3]
Erlotinib + GSK525762 DCXCCYV GSK525762 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
Erlotinib + Sorafenib DCHD8E4 Sorafenib Adenocarcinoma (Cell Line: CAOV3) [3]
Erlotinib + Sorafenib DCUVYY3 Sorafenib Adenocarcinoma (Cell Line: OVCAR3) [3]
Erlotinib + Sorafenib DCZKXYH Sorafenib Adenocarcinoma (Cell Line: A427) [3]
Erlotinib + Sorafenib DC2CJCA Sorafenib Adenocarcinoma (Cell Line: NCIH1650) [3]
Erlotinib + Sorafenib DCMHKXM Sorafenib Adenocarcinoma (Cell Line: NCIH23) [3]
Erlotinib + Sorafenib DC6BK75 Sorafenib Adenocarcinoma (Cell Line: NCIH520) [3]
Erlotinib + Sorafenib DCF2HRT Sorafenib Adenocarcinoma (Cell Line: DLD1) [3]
Erlotinib + Sorafenib DC69K63 Sorafenib Adenocarcinoma (Cell Line: HCT116) [3]
Erlotinib + Sorafenib DCLC9MA Sorafenib Adenocarcinoma (Cell Line: HT29) [3]
Erlotinib + Sorafenib DCEQFIW Sorafenib Adenocarcinoma (Cell Line: SW-620) [3]
Erlotinib + Sorafenib DCDMVY5 Sorafenib Amelanotic melanoma (Cell Line: A2058) [3]
Erlotinib + Sorafenib DCRIXT2 Sorafenib Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
Erlotinib + Sorafenib DCFA3OR Sorafenib Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Erlotinib + Sorafenib DC8G4DW Sorafenib Malignant melanoma (Cell Line: A375) [3]
Erlotinib + Sorafenib DCQMTUZ Sorafenib Malignant melanoma (Cell Line: HT144) [3]
Erlotinib + Sorafenib DCOJDYK Sorafenib Malignant melanoma (Cell Line: SKMEL30) [3]
Erlotinib + Sorafenib DCGUZBS Sorafenib Malignant melanoma (Cell Line: UACC62) [3]
Erlotinib + Sorafenib DCZG27L Sorafenib Mesothelioma (Cell Line: MSTO) [3]
Erlotinib + Sorafenib DCY0TPR Sorafenib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
Erlotinib + Sorafenib DCLWIBN Sorafenib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Erlotinib + Sorafenib DCSW0VU Sorafenib Prostate carcinoma (Cell Line: VCAP) [3]
Erlotinib + PF-562271 DC5Y27B PF-562271 Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [3]
Erlotinib + THZ1 DC3D6F3 THZ1 Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [3]
Erlotinib + Doxorubicin DCSCMCP Doxorubicin Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [3]
Erlotinib + Vorinostat DCZQ1IB Vorinostat Adenocarcinoma (Cell Line: CAOV3) [3]
Erlotinib + Vorinostat DCROTWV Vorinostat Adenocarcinoma (Cell Line: A427) [3]
Erlotinib + Vorinostat DCTV7SH Vorinostat Adenocarcinoma (Cell Line: NCIH1650) [3]
Erlotinib + Vorinostat DCASJFL Vorinostat Adenocarcinoma (Cell Line: NCIH2122) [3]
Erlotinib + Vorinostat DC77GFM Vorinostat Adenocarcinoma (Cell Line: NCIH23) [3]
Erlotinib + Vorinostat DC3LMA9 Vorinostat Adenocarcinoma (Cell Line: NCIH520) [3]
Erlotinib + Vorinostat DC91M0Q Vorinostat Adenocarcinoma (Cell Line: COLO320DM) [3]
Erlotinib + Vorinostat DCBYE56 Vorinostat Adenocarcinoma (Cell Line: DLD1) [3]
Erlotinib + Vorinostat DC3WG5W Vorinostat Adenocarcinoma (Cell Line: HCT116) [3]
Erlotinib + Vorinostat DCPZK4L Vorinostat Adenocarcinoma (Cell Line: HT29) [3]
Erlotinib + Vorinostat DCK3GX6 Vorinostat Adenocarcinoma (Cell Line: SW-620) [3]
Erlotinib + Vorinostat DC9PQ9X Vorinostat Amelanotic melanoma (Cell Line: A2058) [3]
Erlotinib + Vorinostat DCHN8GM Vorinostat Germ cell tumour (Cell Line: PA1) [3]
Erlotinib + Vorinostat DCJZSUN Vorinostat Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Erlotinib + Vorinostat DCCE5IO Vorinostat Malignant melanoma (Cell Line: A375) [3]
Erlotinib + Vorinostat DCR7GSG Vorinostat Malignant melanoma (Cell Line: HT144) [3]
Erlotinib + Vorinostat DCAHUD1 Vorinostat Malignant melanoma (Cell Line: RPMI7951) [3]
Erlotinib + Vorinostat DCGSJ0E Vorinostat Malignant melanoma (Cell Line: SKMEL30) [3]
Erlotinib + Vorinostat DCS9F2B Vorinostat Malignant melanoma (Cell Line: UACC62) [3]
Erlotinib + Vorinostat DCTKC4U Vorinostat Mesothelioma (Cell Line: MSTO) [3]
Erlotinib + Vorinostat DCI97RR Vorinostat Non small cell carcinoma (Cell Line: SKMES1) [3]
Erlotinib + Vorinostat DCNZ2LQ Vorinostat Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
Erlotinib + Vorinostat DCLQJHW Vorinostat Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Erlotinib + Vorinostat DC6KA8K Vorinostat Prostate carcinoma (Cell Line: LNCAP) [3]
Erlotinib + Vorinostat DCK7BON Vorinostat Prostate carcinoma (Cell Line: VCAP) [3]
Erlotinib + Dasatinib DCKHMIR Dasatinib Adenocarcinoma (Cell Line: OVCAR3) [3]
Erlotinib + Dasatinib DCXASAS Dasatinib Adenocarcinoma (Cell Line: A427) [3]
Erlotinib + Dasatinib DCOKAIN Dasatinib Adenocarcinoma (Cell Line: NCIH23) [3]
Erlotinib + Dasatinib DCRCUAJ Dasatinib Adenocarcinoma (Cell Line: NCIH520) [3]
Erlotinib + Dasatinib DC4OIWH Dasatinib Adenocarcinoma (Cell Line: DLD1) [3]
Erlotinib + Dasatinib DCW9GXD Dasatinib Adenocarcinoma (Cell Line: HT29) [3]
Erlotinib + Dasatinib DCYM6YE Dasatinib Adenocarcinoma (Cell Line: SW-620) [3]
Erlotinib + Dasatinib DCZK3PI Dasatinib Amelanotic melanoma (Cell Line: A2058) [3]
Erlotinib + Dasatinib DC1DJ4G Dasatinib Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
Erlotinib + Dasatinib DCSSDPU Dasatinib Germ cell tumour (Cell Line: PA1) [3]
Erlotinib + Dasatinib DCS0JUU Dasatinib Malignant melanoma (Cell Line: A375) [3]
Erlotinib + Dasatinib DC1BPHQ Dasatinib Malignant melanoma (Cell Line: RPMI7951) [3]
Erlotinib + Dasatinib DCA3XTU Dasatinib Malignant melanoma (Cell Line: UACC62) [3]
Erlotinib + Dasatinib DCOACYM Dasatinib Non small cell carcinoma (Cell Line: SKMES1) [3]
Erlotinib + Dasatinib DCNXZAK Dasatinib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
Erlotinib + Dasatinib DC64RRG Dasatinib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Erlotinib + Dasatinib DCYZ7TL Dasatinib Prostate carcinoma (Cell Line: LNCAP) [3]
Erlotinib + PD-0325901 DC1GOLX PD-0325901 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Erlotinib + PD-0325901 DC8IMPR PD-0325901 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Erlotinib + PD-0325901 DCBPRBC PD-0325901 Carcinoma (Cell Line: OV90) [4]
Erlotinib + PD-0325901 DCG00WC PD-0325901 Carcinoma (Cell Line: EFM192B) [4]
Erlotinib + PD-0325901 DCB04C9 PD-0325901 Invasive ductal carcinoma (Cell Line: T-47D) [4]
Erlotinib + RTB101 DC769ZM RTB101 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Erlotinib + RTB101 DC099LD RTB101 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Erlotinib + RTB101 DC4CYPD RTB101 Breast carcinoma (Cell Line: KPL1) [4]
Erlotinib + RTB101 DCE1L58 RTB101 Breast carcinoma (Cell Line: OCUBM) [4]
Erlotinib + RTB101 DC5ZZDC RTB101 Carcinoma (Cell Line: OV90) [4]
Erlotinib + RTB101 DCUKLP1 RTB101 Carcinoma (Cell Line: EFM192B) [4]
Erlotinib + RTB101 DC6FV1T RTB101 Carcinoma (Cell Line: MDAMB436) [4]
Erlotinib + RTB101 DCB0DWC RTB101 Invasive ductal carcinoma (Cell Line: T-47D) [4]
Erlotinib + RTB101 DCC6W02 RTB101 Rectal adenocarcinoma (Cell Line: SW837) [4]
Erlotinib + SCH-900776 DCMBPBM SCH-900776 Carcinoma (Cell Line: OV90) [4]
Erlotinib + SCH-900776 DCK7YBM SCH-900776 Carcinoma (Cell Line: EFM192B) [4]
Erlotinib + SCH-900776 DCE0BDL SCH-900776 Rectal adenocarcinoma (Cell Line: SW837) [4]
Erlotinib + 10-hydroxycamptothecin DCF5V77 10-hydroxycamptothecin Breast carcinoma (Cell Line: ZR751) [4]
Erlotinib + 10-hydroxycamptothecin DCNI3YD 10-hydroxycamptothecin Breast carcinoma (Cell Line: KPL1) [4]
Erlotinib + 10-hydroxycamptothecin DCDSBTQ 10-hydroxycamptothecin Breast carcinoma (Cell Line: OCUBM) [4]
Erlotinib + 10-hydroxycamptothecin DCM9BX0 10-hydroxycamptothecin Carcinoma (Cell Line: EFM192B) [4]
Erlotinib + 10-hydroxycamptothecin DCBXWUE 10-hydroxycamptothecin Carcinoma (Cell Line: MDAMB436) [4]
Erlotinib + 10-hydroxycamptothecin DCZZMOX 10-hydroxycamptothecin Colon adenocarcinoma (Cell Line: LOVO) [4]
Erlotinib + 10-hydroxycamptothecin DCPWB4E 10-hydroxycamptothecin Colon carcinoma (Cell Line: RKO) [4]
Erlotinib + 10-hydroxycamptothecin DC818JB 10-hydroxycamptothecin Invasive ductal carcinoma (Cell Line: T-47D) [4]
Erlotinib + 10-hydroxycamptothecin DCTRE1E 10-hydroxycamptothecin Rectal adenocarcinoma (Cell Line: SW837) [4]
Erlotinib + SNX-2112 DCARUUS SNX-2112 Breast carcinoma (Cell Line: KPL1) [4]
Erlotinib + SNX-2112 DCF47VW SNX-2112 Breast carcinoma (Cell Line: OCUBM) [4]
Erlotinib + SNX-2112 DC1AHT3 SNX-2112 Carcinoma (Cell Line: OV90) [4]
Erlotinib + SNX-2112 DCQNIBK SNX-2112 Carcinoma (Cell Line: EFM192B) [4]
Erlotinib + SNX-2112 DCWSOXW SNX-2112 Carcinoma (Cell Line: MDAMB436) [4]
Erlotinib + SNX-2112 DCWN5F0 SNX-2112 Invasive ductal carcinoma (Cell Line: T-47D) [4]
Erlotinib + Ridaforolimus DCHXF6G Ridaforolimus Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Erlotinib + Ridaforolimus DCTO9BJ Ridaforolimus Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Erlotinib + Ridaforolimus DCR9IU3 Ridaforolimus Breast carcinoma (Cell Line: KPL1) [4]
Erlotinib + Ridaforolimus DCS17XZ Ridaforolimus Carcinoma (Cell Line: OV90) [4]
Erlotinib + Ridaforolimus DCKUQFO Ridaforolimus Carcinoma (Cell Line: EFM192B) [4]
Erlotinib + Ridaforolimus DC8Q3MD Ridaforolimus Colon adenocarcinoma (Cell Line: LOVO) [4]
Erlotinib + Ridaforolimus DC9YWTC Ridaforolimus Invasive ductal carcinoma (Cell Line: T-47D) [4]
Erlotinib + Ridaforolimus DCVDVPX Ridaforolimus Rectal adenocarcinoma (Cell Line: SW837) [4]
Erlotinib + MK-4827 DCG60RJ MK-4827 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Erlotinib + MK-4827 DCKE86M MK-4827 Breast carcinoma (Cell Line: KPL1) [4]
Erlotinib + MK-4827 DCWNPQ6 MK-4827 Breast carcinoma (Cell Line: OCUBM) [4]
Erlotinib + MK-4827 DCXXSJO MK-4827 Carcinoma (Cell Line: OV90) [4]
Erlotinib + MK-4827 DC3VAAH MK-4827 Carcinoma (Cell Line: EFM192B) [4]
Erlotinib + MK-4827 DCZANBO MK-4827 Colon adenocarcinoma (Cell Line: LOVO) [4]
Erlotinib + MK-4827 DCGQRYB MK-4827 Colon carcinoma (Cell Line: RKO) [4]
Erlotinib + MK-4827 DCLC4QF MK-4827 Invasive ductal carcinoma (Cell Line: T-47D) [4]
Erlotinib + MK-4827 DCNS45Z MK-4827 Rectal adenocarcinoma (Cell Line: SW837) [4]
Erlotinib + Lomustine DCK71ZE Lomustine Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Erlotinib + Lomustine DCOMJPI Lomustine Breast carcinoma (Cell Line: OCUBM) [4]
Erlotinib + Bortezomib DCHPRKQ Bortezomib Breast carcinoma (Cell Line: KPL1) [4]
Erlotinib + Bortezomib DCJSK1Y Bortezomib Carcinoma (Cell Line: OV90) [4]
Erlotinib + Bortezomib DC6XJ6D Bortezomib Carcinoma (Cell Line: EFM192B) [4]
Erlotinib + Bortezomib DC4BUJ0 Bortezomib Colon carcinoma (Cell Line: RKO) [4]
Erlotinib + Bortezomib DCCKS0O Bortezomib Rectal adenocarcinoma (Cell Line: SW837) [4]
Erlotinib + GSK525762 DCUMHWB GSK525762 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Erlotinib + GSK525762 DC2HLXW GSK525762 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Erlotinib + Sorafenib DCYH4HT Sorafenib Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Erlotinib + Sorafenib DCCHKIG Sorafenib Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Erlotinib + Sorafenib DCLS2SF Sorafenib Breast carcinoma (Cell Line: ZR751) [4]
Erlotinib + Sorafenib DCV24P1 Sorafenib Breast carcinoma (Cell Line: KPL1) [4]
Erlotinib + Sorafenib DCEDSMG Sorafenib Breast carcinoma (Cell Line: OCUBM) [4]
Erlotinib + Sorafenib DC956TS Sorafenib Carcinoma (Cell Line: OV90) [4]
Erlotinib + Sorafenib DCLDEZ1 Sorafenib Carcinoma (Cell Line: MDAMB436) [4]
Erlotinib + Sorafenib DCBLIUB Sorafenib Colon carcinoma (Cell Line: RKO) [4]
Erlotinib + Vorinostat DCVICYB Vorinostat Breast carcinoma (Cell Line: KPL1) [4]
Erlotinib + Vorinostat DCAS83L Vorinostat Breast carcinoma (Cell Line: OCUBM) [4]
Erlotinib + Vorinostat DCMNB4G Vorinostat Carcinoma (Cell Line: OV90) [4]
Erlotinib + Vorinostat DC49T0S Vorinostat Carcinoma (Cell Line: EFM192B) [4]
Erlotinib + Vorinostat DCSL948 Vorinostat Carcinoma (Cell Line: MDAMB436) [4]
Erlotinib + Vorinostat DCUCT7E Vorinostat Colon adenocarcinoma (Cell Line: LOVO) [4]
Erlotinib + Vorinostat DC2IX4Q Vorinostat Colon carcinoma (Cell Line: RKO) [4]
Erlotinib + Vorinostat DC9XEIA Vorinostat Invasive ductal carcinoma (Cell Line: T-47D) [4]
Erlotinib + Vorinostat DC0MJS2 Vorinostat Rectal adenocarcinoma (Cell Line: SW837) [4]
Erlotinib + Dasatinib DC5XSKM Dasatinib Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Erlotinib + Dasatinib DCPBR00 Dasatinib Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Erlotinib + Dasatinib DCUMG8Y Dasatinib Breast carcinoma (Cell Line: OCUBM) [4]
Erlotinib + Dasatinib DCJYWIX Dasatinib Carcinoma (Cell Line: OV90) [4]
Erlotinib + Dasatinib DCZZATX Dasatinib Carcinoma (Cell Line: EFM192B) [4]
Erlotinib + Dasatinib DCAF0MC Dasatinib Carcinoma (Cell Line: MDAMB436) [4]
Estramustine + Erlotinib DCZCDJO Estramustine Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
Estramustine + Erlotinib DCL87OK Estramustine Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Estramustine + Erlotinib DCSDGM8 Estramustine Breast carcinoma (Cell Line: OCUBM) [4]
Estramustine + Erlotinib DC84A3A Estramustine Carcinoma (Cell Line: EFM192B) [4]
Estramustine + Erlotinib DCUCEBZ Estramustine Colon adenocarcinoma (Cell Line: LOVO) [4]
Estramustine + Erlotinib DC1XT6A Estramustine Colon carcinoma (Cell Line: RKO) [4]
Estramustine + Erlotinib DC07Z8U Estramustine Invasive ductal carcinoma (Cell Line: T-47D) [4]
Estramustine + Erlotinib DC09RVN Estramustine Adenocarcinoma (Cell Line: OVCAR3) [5]
Estramustine + Erlotinib DCNUD6B Estramustine Adenocarcinoma (Cell Line: NCIH2122) [5]
Estramustine + Erlotinib DCTVHIA Estramustine Adenocarcinoma (Cell Line: COLO320DM) [5]
Estramustine + Erlotinib DCAODRI Estramustine Adenocarcinoma (Cell Line: HT29) [5]
Estramustine + Erlotinib DC0WVH4 Estramustine Adenocarcinoma (Cell Line: SW-620) [5]
Estramustine + Erlotinib DC0TU8K Estramustine Amelanotic melanoma (Cell Line: A2058) [5]
Estramustine + Erlotinib DCFSS8I Estramustine Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Estramustine + Erlotinib DCRGM44 Estramustine Malignant melanoma (Cell Line: A375) [5]
Estramustine + Erlotinib DC2PCL9 Estramustine Malignant melanoma (Cell Line: HT144) [5]
Estramustine + Erlotinib DCN2962 Estramustine Malignant melanoma (Cell Line: RPMI7951) [5]
Estramustine + Erlotinib DC1EM91 Estramustine Malignant melanoma (Cell Line: UACC62) [5]
Estramustine + Erlotinib DCVS3W2 Estramustine Mesothelioma (Cell Line: MSTO) [5]
Estramustine + Erlotinib DCXJB7E Estramustine Non small cell carcinoma (Cell Line: SKMES1) [5]
Estramustine + Erlotinib DCKQ987 Estramustine Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Estramustine + Erlotinib DCI0N3D Estramustine Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Estramustine + Erlotinib DCMGXD5 Estramustine Prostate carcinoma (Cell Line: LNCAP) [5]
Estramustine + Erlotinib DC7HOPS Estramustine Prostate carcinoma (Cell Line: VCAP) [5]
Etoposide + Erlotinib DC3YHKV Etoposide Adenocarcinoma (Cell Line: CAOV3) [3]
Etoposide + Erlotinib DCI6C05 Etoposide Adenocarcinoma (Cell Line: A427) [3]
Etoposide + Erlotinib DCSVFBW Etoposide Adenocarcinoma (Cell Line: NCIH1650) [3]
Etoposide + Erlotinib DCUC0UZ Etoposide Adenocarcinoma (Cell Line: NCIH2122) [3]
Etoposide + Erlotinib DC30ZB7 Etoposide Adenocarcinoma (Cell Line: NCIH520) [3]
Etoposide + Erlotinib DCB30RD Etoposide Adenocarcinoma (Cell Line: COLO320DM) [3]
Etoposide + Erlotinib DC63PYD Etoposide Adenocarcinoma (Cell Line: DLD1) [3]
Etoposide + Erlotinib DCVHS5C Etoposide Adenocarcinoma (Cell Line: HCT116) [3]
Etoposide + Erlotinib DCG6CWP Etoposide Adenocarcinoma (Cell Line: HT29) [3]
Etoposide + Erlotinib DCTCG3W Etoposide Adenocarcinoma (Cell Line: SW-620) [3]
Etoposide + Erlotinib DC2YI0K Etoposide Amelanotic melanoma (Cell Line: A2058) [3]
Etoposide + Erlotinib DCRBX9C Etoposide Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Etoposide + Erlotinib DCQR8F5 Etoposide Malignant melanoma (Cell Line: A375) [3]
Etoposide + Erlotinib DC5KBP3 Etoposide Malignant melanoma (Cell Line: HT144) [3]
Etoposide + Erlotinib DC5ECPF Etoposide Malignant melanoma (Cell Line: RPMI7951) [3]
Etoposide + Erlotinib DC86MOO Etoposide Malignant melanoma (Cell Line: SKMEL30) [3]
Etoposide + Erlotinib DCCIMT7 Etoposide Malignant melanoma (Cell Line: UACC62) [3]
Etoposide + Erlotinib DCWW83N Etoposide Mesothelioma (Cell Line: MSTO) [3]
Etoposide + Erlotinib DC59P1V Etoposide Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
Etoposide + Erlotinib DCMZ603 Etoposide Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Etoposide + Erlotinib DCF8TUO Etoposide Prostate carcinoma (Cell Line: LNCAP) [3]
Etoposide + Erlotinib DC1O6ES Etoposide Prostate carcinoma (Cell Line: VCAP) [3]
Etoposide + Erlotinib DC6JUJF Etoposide Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Etoposide + Erlotinib DCDGFJ8 Etoposide Breast carcinoma (Cell Line: ZR751) [4]
Etoposide + Erlotinib DC7UWCB Etoposide Breast carcinoma (Cell Line: OCUBM) [4]
Etoposide + Erlotinib DC5O3FL Etoposide Carcinoma (Cell Line: OV90) [4]
Etoposide + Erlotinib DCXQJMS Etoposide Carcinoma (Cell Line: EFM192B) [4]
Etoposide + Erlotinib DC7U7VY Etoposide Carcinoma (Cell Line: MDAMB436) [4]
Etoposide + Erlotinib DCPIN8K Etoposide Colon carcinoma (Cell Line: RKO) [4]
Etoposide + Erlotinib DCFOVH8 Etoposide Invasive ductal carcinoma (Cell Line: T-47D) [4]
Etoposide + Erlotinib DCVGNAZ Etoposide Rectal adenocarcinoma (Cell Line: SW837) [4]
Fluorouracil + Erlotinib DC0PXP4 Fluorouracil Adenocarcinoma (Cell Line: DLD1) [3]
Fluorouracil + Erlotinib DC6GJ5O Fluorouracil Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
Fluorouracil + Erlotinib DCW2L30 Fluorouracil Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Fluorouracil + Erlotinib DCMSHKT Fluorouracil Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Fluorouracil + Erlotinib DCWW9WK Fluorouracil Breast carcinoma (Cell Line: KPL1) [4]
Fluorouracil + Erlotinib DCISOID Fluorouracil Breast carcinoma (Cell Line: OCUBM) [4]
Fluorouracil + Erlotinib DCW622Q Fluorouracil Colon adenocarcinoma (Cell Line: LOVO) [4]
Fluorouracil + Erlotinib DCPS2ZQ Fluorouracil Colon carcinoma (Cell Line: RKO) [4]
Fluorouracil + Erlotinib DCTZ8JI Fluorouracil Invasive ductal carcinoma (Cell Line: T-47D) [4]
Fluorouracil + Erlotinib DCGU6MD Fluorouracil Rectal adenocarcinoma (Cell Line: SW837) [4]
Fluorouracil + Erlotinib DCRDQ10 Fluorouracil Adenocarcinoma (Cell Line: CAOV3) [5]
Fluorouracil + Erlotinib DCVWULN Fluorouracil Adenocarcinoma (Cell Line: OVCAR3) [5]
Fluorouracil + Erlotinib DCYAQ85 Fluorouracil Adenocarcinoma (Cell Line: A427) [5]
Fluorouracil + Erlotinib DC1FKDB Fluorouracil Adenocarcinoma (Cell Line: NCIH1650) [5]
Fluorouracil + Erlotinib DCQLUV5 Fluorouracil Adenocarcinoma (Cell Line: NCIH2122) [5]
Fluorouracil + Erlotinib DC3DZHV Fluorouracil Adenocarcinoma (Cell Line: NCIH23) [5]
Fluorouracil + Erlotinib DCGPT6R Fluorouracil Adenocarcinoma (Cell Line: NCIH520) [5]
Fluorouracil + Erlotinib DCZZ5XF Fluorouracil Adenocarcinoma (Cell Line: COLO320DM) [5]
Fluorouracil + Erlotinib DCQVIX9 Fluorouracil Adenocarcinoma (Cell Line: HCT116) [5]
Fluorouracil + Erlotinib DCECZA8 Fluorouracil Adenocarcinoma (Cell Line: HT29) [5]
Fluorouracil + Erlotinib DCA04XA Fluorouracil Adenocarcinoma (Cell Line: SW-620) [5]
Fluorouracil + Erlotinib DC48752 Fluorouracil Germ cell tumour (Cell Line: PA1) [5]
Fluorouracil + Erlotinib DCJUCAV Fluorouracil Malignant melanoma (Cell Line: A375) [5]
Fluorouracil + Erlotinib DC3I5GN Fluorouracil Malignant melanoma (Cell Line: RPMI7951) [5]
Fluorouracil + Erlotinib DC3GSPS Fluorouracil Malignant melanoma (Cell Line: SKMEL30) [5]
Fluorouracil + Erlotinib DCSUB9D Fluorouracil Malignant melanoma (Cell Line: UACC62) [5]
Fluorouracil + Erlotinib DCEYIS9 Fluorouracil Mesothelioma (Cell Line: MSTO) [5]
Fluorouracil + Erlotinib DCSC54Z Fluorouracil Non small cell carcinoma (Cell Line: SKMES1) [5]
Fluorouracil + Erlotinib DCFE5XZ Fluorouracil Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Fluorouracil + Erlotinib DCDM2MA Fluorouracil Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Gemcitabine + Erlotinib DCBWPY0 Gemcitabine Adenocarcinoma (Cell Line: A427) [3]
Gemcitabine + Erlotinib DCQH8VI Gemcitabine Adenocarcinoma (Cell Line: NCIH2122) [3]
Gemcitabine + Erlotinib DC91R2U Gemcitabine Adenocarcinoma (Cell Line: NCIH520) [3]
Gemcitabine + Erlotinib DC8HVXM Gemcitabine Adenocarcinoma (Cell Line: COLO320DM) [3]
Gemcitabine + Erlotinib DCORV6W Gemcitabine Adenocarcinoma (Cell Line: DLD1) [3]
Gemcitabine + Erlotinib DC8IUHE Gemcitabine Adenocarcinoma (Cell Line: HT29) [3]
Gemcitabine + Erlotinib DC9W669 Gemcitabine Adenocarcinoma (Cell Line: SW-620) [3]
Gemcitabine + Erlotinib DCP3927 Gemcitabine Amelanotic melanoma (Cell Line: A2058) [3]
Gemcitabine + Erlotinib DCCQU7I Gemcitabine Germ cell tumour (Cell Line: PA1) [3]
Gemcitabine + Erlotinib DCG1YHA Gemcitabine Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Gemcitabine + Erlotinib DCQ4FWJ Gemcitabine Malignant melanoma (Cell Line: HT144) [3]
Gemcitabine + Erlotinib DCZAQPJ Gemcitabine Malignant melanoma (Cell Line: SKMEL30) [3]
Gemcitabine + Erlotinib DCRFBS7 Gemcitabine Malignant melanoma (Cell Line: UACC62) [3]
Gemcitabine + Erlotinib DCMXYEZ Gemcitabine Mesothelioma (Cell Line: MSTO) [3]
Gemcitabine + Erlotinib DCH6LPN Gemcitabine Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
Gemcitabine + Erlotinib DCICFF1 Gemcitabine Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Gemcitabine + Erlotinib DC3RJXF Gemcitabine Prostate carcinoma (Cell Line: LNCAP) [3]
Gemcitabine + Erlotinib DCFGUY8 Gemcitabine Breast carcinoma (Cell Line: ZR751) [4]
Gemcitabine + Erlotinib DC1OXSA Gemcitabine Breast carcinoma (Cell Line: KPL1) [4]
Gemcitabine + Erlotinib DCCCRVE Gemcitabine Breast carcinoma (Cell Line: OCUBM) [4]
Gemcitabine + Erlotinib DC7WKBF Gemcitabine Carcinoma (Cell Line: EFM192B) [4]
Gemcitabine + Erlotinib DCVGXBU Gemcitabine Carcinoma (Cell Line: MDAMB436) [4]
Gemcitabine + Erlotinib DC0RDBN Gemcitabine Colon carcinoma (Cell Line: RKO) [4]
Gemcitabine + Erlotinib DC2CYQX Gemcitabine Rectal adenocarcinoma (Cell Line: SW837) [4]
Idarubicin + Erlotinib DCYQQBE Idarubicin Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
Idarubicin + Erlotinib DCQA8PI Idarubicin Adenocarcinoma (Cell Line: A427) [5]
Idarubicin + Erlotinib DCJ5U1J Idarubicin Adenocarcinoma (Cell Line: NCIH2122) [5]
Idarubicin + Erlotinib DCS3UVL Idarubicin Adenocarcinoma (Cell Line: COLO320DM) [5]
Idarubicin + Erlotinib DCPE80I Idarubicin Adenocarcinoma (Cell Line: SW-620) [5]
Idarubicin + Erlotinib DC2OJIG Idarubicin Amelanotic melanoma (Cell Line: A2058) [5]
Idarubicin + Erlotinib DCYJ7YF Idarubicin Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Idarubicin + Erlotinib DCHNNUF Idarubicin Malignant melanoma (Cell Line: RPMI7951) [5]
Idarubicin + Erlotinib DCW4WK8 Idarubicin Malignant melanoma (Cell Line: UACC62) [5]
Idarubicin + Erlotinib DCWAD5N Idarubicin Malignant melanoma (Cell Line: A375) [5]
Idarubicin + Erlotinib DCI8GK2 Idarubicin Mesothelioma (Cell Line: MSTO) [5]
Idarubicin + Erlotinib DCPF2BZ Idarubicin Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Lapatinib + Erlotinib DCD6B4L Lapatinib Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Lapatinib + Erlotinib DCE34OB Lapatinib Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Lapatinib + Erlotinib DCRZWQR Lapatinib Breast carcinoma (Cell Line: OCUBM) [4]
Lapatinib + Erlotinib DCKG5NK Lapatinib Carcinoma (Cell Line: OV90) [4]
Lapatinib + Erlotinib DCMC89G Lapatinib Carcinoma (Cell Line: EFM192B) [4]
Lapatinib + Erlotinib DC8SBDV Lapatinib Adenocarcinoma (Cell Line: A427) [5]
Lapatinib + Erlotinib DCXXX1P Lapatinib Adenocarcinoma (Cell Line: NCIH2122) [5]
Lapatinib + Erlotinib DC81U1C Lapatinib Adenocarcinoma (Cell Line: NCIH520) [5]
Lapatinib + Erlotinib DCYBSA7 Lapatinib Adenocarcinoma (Cell Line: COLO320DM) [5]
Lapatinib + Erlotinib DC1NGLF Lapatinib Adenocarcinoma (Cell Line: DLD1) [5]
Lapatinib + Erlotinib DC8EGOU Lapatinib Adenocarcinoma (Cell Line: HT29) [5]
Lapatinib + Erlotinib DC6R27Z Lapatinib Amelanotic melanoma (Cell Line: A2058) [5]
Lapatinib + Erlotinib DCHK3Q3 Lapatinib Germ cell tumour (Cell Line: PA1) [5]
Lapatinib + Erlotinib DC42OPM Lapatinib Malignant melanoma (Cell Line: UACC62) [5]
Lapatinib + Erlotinib DCC65MV Lapatinib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Lapatinib + Erlotinib DCSDOD2 Lapatinib Prostate carcinoma (Cell Line: LNCAP) [5]
Metformin + Erlotinib DCA2XMW Metformin Adenocarcinoma (Cell Line: NCIH2122) [3]
Metformin + Erlotinib DCJ5SO7 Metformin Adenocarcinoma (Cell Line: HT29) [3]
Metformin + Erlotinib DCFEU8Q Metformin Adenocarcinoma (Cell Line: SW-620) [3]
Metformin + Erlotinib DCKFJPG Metformin Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
Metformin + Erlotinib DC81PQ0 Metformin Mesothelioma (Cell Line: MSTO) [3]
Metformin + Erlotinib DC1GB5N Metformin Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Metformin + Erlotinib DCTBIHC Metformin Breast carcinoma (Cell Line: OCUBM) [4]
Methotrexate + Erlotinib DC2N846 Methotrexate Adenocarcinoma (Cell Line: A427) [3]
Methotrexate + Erlotinib DC82KVI Methotrexate Adenocarcinoma (Cell Line: NCIH1650) [3]
Methotrexate + Erlotinib DCBFOQA Methotrexate Adenocarcinoma (Cell Line: NCIH23) [3]
Methotrexate + Erlotinib DCBJJZ2 Methotrexate Adenocarcinoma (Cell Line: SW-620) [3]
Methotrexate + Erlotinib DCDWV4E Methotrexate Germ cell tumour (Cell Line: PA1) [3]
Methotrexate + Erlotinib DCMIU92 Methotrexate Malignant melanoma (Cell Line: A375) [3]
Methotrexate + Erlotinib DCIG80N Methotrexate Malignant melanoma (Cell Line: UACC62) [3]
Methotrexate + Erlotinib DCO3XY6 Methotrexate Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Methotrexate + Erlotinib DCPQUG8 Methotrexate Prostate carcinoma (Cell Line: LNCAP) [3]
Methotrexate + Erlotinib DCP0HK8 Methotrexate Prostate carcinoma (Cell Line: VCAP) [3]
Methotrexate + Erlotinib DC0WXBB Methotrexate Carcinoma (Cell Line: EFM192B) [4]
Mitomycin + Erlotinib DCFNYLH Mitomycin Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Mitomycin + Erlotinib DCR23NK Mitomycin Mesothelioma (Cell Line: MSTO) [5]
MK-1775 + Erlotinib DC92V49 MK-1775 Adenocarcinoma (Cell Line: CAOV3) [3]
MK-1775 + Erlotinib DCTO1SJ MK-1775 Adenocarcinoma (Cell Line: NCIH1650) [3]
MK-1775 + Erlotinib DCEZJXP MK-1775 Adenocarcinoma (Cell Line: NCIH2122) [3]
MK-1775 + Erlotinib DCK3IEP MK-1775 Adenocarcinoma (Cell Line: NCIH520) [3]
MK-1775 + Erlotinib DCDA56W MK-1775 Adenocarcinoma (Cell Line: COLO320DM) [3]
MK-1775 + Erlotinib DCMFK7Q MK-1775 Adenocarcinoma (Cell Line: HCT116) [3]
MK-1775 + Erlotinib DCJ3FI1 MK-1775 Adenocarcinoma (Cell Line: HT29) [3]
MK-1775 + Erlotinib DCHY8DA MK-1775 Adenocarcinoma (Cell Line: SW-620) [3]
MK-1775 + Erlotinib DC7CN19 MK-1775 Amelanotic melanoma (Cell Line: A2058) [3]
MK-1775 + Erlotinib DCVEAFS MK-1775 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
MK-1775 + Erlotinib DCKPLK7 MK-1775 Germ cell tumour (Cell Line: PA1) [3]
MK-1775 + Erlotinib DC8JI6U MK-1775 Large cell lung carcinoma (Cell Line: NCI-H460) [3]
MK-1775 + Erlotinib DCOEWRR MK-1775 Malignant melanoma (Cell Line: A375) [3]
MK-1775 + Erlotinib DC45ENQ MK-1775 Malignant melanoma (Cell Line: SKMEL30) [3]
MK-1775 + Erlotinib DCMV16H MK-1775 Malignant melanoma (Cell Line: UACC62) [3]
MK-1775 + Erlotinib DC9QV02 MK-1775 Mesothelioma (Cell Line: MSTO) [3]
MK-1775 + Erlotinib DCEG4FJ MK-1775 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
MK-1775 + Erlotinib DCWS8F2 MK-1775 Prostate carcinoma (Cell Line: VCAP) [3]
MK-1775 + Erlotinib DCVTOT1 MK-1775 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
MK-1775 + Erlotinib DCBHNVH MK-1775 Breast carcinoma (Cell Line: KPL1) [4]
MK-1775 + Erlotinib DCKLEMV MK-1775 Breast carcinoma (Cell Line: OCUBM) [4]
MK-1775 + Erlotinib DCZLMSY MK-1775 Carcinoma (Cell Line: EFM192B) [4]
MK-1775 + Erlotinib DCANMCQ MK-1775 Colon adenocarcinoma (Cell Line: LOVO) [4]
MK-1775 + Erlotinib DCVL1HK MK-1775 Colon carcinoma (Cell Line: RKO) [4]
MK-1775 + Erlotinib DCFIU4D MK-1775 Rectal adenocarcinoma (Cell Line: SW837) [4]
MK-2206 + Erlotinib DCJPLDH MK-2206 Adenocarcinoma (Cell Line: CAOV3) [3]
MK-2206 + Erlotinib DCJB8MD MK-2206 Adenocarcinoma (Cell Line: OVCAR3) [3]
MK-2206 + Erlotinib DCGXAII MK-2206 Adenocarcinoma (Cell Line: A427) [3]
MK-2206 + Erlotinib DCOCWP7 MK-2206 Adenocarcinoma (Cell Line: NCIH1650) [3]
MK-2206 + Erlotinib DCPMTYR MK-2206 Adenocarcinoma (Cell Line: NCIH2122) [3]
MK-2206 + Erlotinib DC4631E MK-2206 Adenocarcinoma (Cell Line: NCIH23) [3]
MK-2206 + Erlotinib DCEB0J1 MK-2206 Adenocarcinoma (Cell Line: NCIH520) [3]
MK-2206 + Erlotinib DCPM2QW MK-2206 Adenocarcinoma (Cell Line: COLO320DM) [3]
MK-2206 + Erlotinib DC0983O MK-2206 Adenocarcinoma (Cell Line: DLD1) [3]
MK-2206 + Erlotinib DC4IT7X MK-2206 Adenocarcinoma (Cell Line: HCT116) [3]
MK-2206 + Erlotinib DCW9RYR MK-2206 Adenocarcinoma (Cell Line: HT29) [3]
MK-2206 + Erlotinib DC34EVG MK-2206 Adenocarcinoma (Cell Line: SW-620) [3]
MK-2206 + Erlotinib DC81C28 MK-2206 Amelanotic melanoma (Cell Line: A2058) [3]
MK-2206 + Erlotinib DCVDI8P MK-2206 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
MK-2206 + Erlotinib DC94AAK MK-2206 Germ cell tumour (Cell Line: PA1) [3]
MK-2206 + Erlotinib DCJ15YY MK-2206 Large cell lung carcinoma (Cell Line: NCI-H460) [3]
MK-2206 + Erlotinib DCXEPOG MK-2206 Malignant melanoma (Cell Line: A375) [3]
MK-2206 + Erlotinib DC1JTTT MK-2206 Malignant melanoma (Cell Line: HT144) [3]
MK-2206 + Erlotinib DC8ZOOL MK-2206 Malignant melanoma (Cell Line: RPMI7951) [3]
MK-2206 + Erlotinib DCIUMOL MK-2206 Malignant melanoma (Cell Line: SKMEL30) [3]
MK-2206 + Erlotinib DC1VFU2 MK-2206 Malignant melanoma (Cell Line: UACC62) [3]
MK-2206 + Erlotinib DCBMMHW MK-2206 Mesothelioma (Cell Line: MSTO) [3]
MK-2206 + Erlotinib DCQT8AB MK-2206 Non small cell carcinoma (Cell Line: SKMES1) [3]
MK-2206 + Erlotinib DCXSK54 MK-2206 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
MK-2206 + Erlotinib DCEIB1X MK-2206 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
MK-2206 + Erlotinib DCYJO35 MK-2206 Prostate carcinoma (Cell Line: LNCAP) [3]
MK-2206 + Erlotinib DCI3FI3 MK-2206 Prostate carcinoma (Cell Line: VCAP) [3]
MK-2206 + Erlotinib DC6VW52 MK-2206 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
MK-2206 + Erlotinib DCIPQGO MK-2206 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
MK-2206 + Erlotinib DCAO7P7 MK-2206 Breast carcinoma (Cell Line: ZR751) [4]
MK-2206 + Erlotinib DC59C9R MK-2206 Breast carcinoma (Cell Line: KPL1) [4]
MK-2206 + Erlotinib DCHPRV2 MK-2206 Breast carcinoma (Cell Line: OCUBM) [4]
MK-2206 + Erlotinib DCOQAG9 MK-2206 Carcinoma (Cell Line: OV90) [4]
MK-2206 + Erlotinib DCUXMSD MK-2206 Carcinoma (Cell Line: EFM192B) [4]
MK-2206 + Erlotinib DCGFZ9N MK-2206 Carcinoma (Cell Line: MDAMB436) [4]
MK-2206 + Erlotinib DCCTDIE MK-2206 Colon carcinoma (Cell Line: RKO) [4]
MK-2206 + Erlotinib DCVJTJK MK-2206 Rectal adenocarcinoma (Cell Line: SW837) [4]
MK-5108 + Erlotinib DCOBHS3 MK-5108 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
MK-5108 + Erlotinib DCS8BJ2 MK-5108 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
MK-5108 + Erlotinib DCFUGT7 MK-5108 Breast carcinoma (Cell Line: KPL1) [4]
MK-5108 + Erlotinib DCIC8RS MK-5108 Breast carcinoma (Cell Line: OCUBM) [4]
MK-5108 + Erlotinib DCDD06T MK-5108 Carcinoma (Cell Line: EFM192B) [4]
MK-5108 + Erlotinib DCN4N4F MK-5108 Colon adenocarcinoma (Cell Line: LOVO) [4]
MK-5108 + Erlotinib DC3MKVG MK-5108 Colon carcinoma (Cell Line: RKO) [4]
MK-5108 + Erlotinib DCTE8LK MK-5108 Invasive ductal carcinoma (Cell Line: T-47D) [4]
MK-5108 + Erlotinib DCI88SZ MK-5108 Rectal adenocarcinoma (Cell Line: SW837) [4]
MK-5108 + Erlotinib DCM4Q20 MK-5108 Adenocarcinoma (Cell Line: OVCAR3) [5]
MK-5108 + Erlotinib DC1ZH7A MK-5108 Adenocarcinoma (Cell Line: CAOV3) [5]
MK-5108 + Erlotinib DCLHP24 MK-5108 Adenocarcinoma (Cell Line: A427) [5]
MK-5108 + Erlotinib DCG37J1 MK-5108 Adenocarcinoma (Cell Line: NCIH1650) [5]
MK-5108 + Erlotinib DCPXROO MK-5108 Adenocarcinoma (Cell Line: NCIH2122) [5]
MK-5108 + Erlotinib DC76B4I MK-5108 Adenocarcinoma (Cell Line: NCIH23) [5]
MK-5108 + Erlotinib DC5TJ1Q MK-5108 Adenocarcinoma (Cell Line: NCIH520) [5]
MK-5108 + Erlotinib DCYSN5X MK-5108 Adenocarcinoma (Cell Line: COLO320DM) [5]
MK-5108 + Erlotinib DCK4QKP MK-5108 Adenocarcinoma (Cell Line: DLD1) [5]
MK-5108 + Erlotinib DCS3U2A MK-5108 Adenocarcinoma (Cell Line: HT29) [5]
MK-5108 + Erlotinib DCKVT7V MK-5108 Adenocarcinoma (Cell Line: SW-620) [5]
MK-5108 + Erlotinib DCXAF9D MK-5108 Adenocarcinoma (Cell Line: HCT116) [5]
MK-5108 + Erlotinib DCIO91C MK-5108 Amelanotic melanoma (Cell Line: A2058) [5]
MK-5108 + Erlotinib DCBZQZR MK-5108 Germ cell tumour (Cell Line: PA1) [5]
MK-5108 + Erlotinib DC1OL2T MK-5108 Large cell lung carcinoma (Cell Line: NCI-H460) [5]
MK-5108 + Erlotinib DCX2EF7 MK-5108 Malignant melanoma (Cell Line: HT144) [5]
MK-5108 + Erlotinib DCKGI43 MK-5108 Malignant melanoma (Cell Line: RPMI7951) [5]
MK-5108 + Erlotinib DCQV03K MK-5108 Malignant melanoma (Cell Line: SKMEL30) [5]
MK-5108 + Erlotinib DCVANOK MK-5108 Malignant melanoma (Cell Line: UACC62) [5]
MK-5108 + Erlotinib DC4KM6B MK-5108 Malignant melanoma (Cell Line: A375) [5]
MK-5108 + Erlotinib DCR914L MK-5108 Mesothelioma (Cell Line: MSTO) [5]
MK-5108 + Erlotinib DC51XGC MK-5108 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
MK-5108 + Erlotinib DCA4D1Y MK-5108 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
MK-5108 + Erlotinib DC0PT5I MK-5108 Prostate carcinoma (Cell Line: LNCAP) [5]
MK-5108 + Erlotinib DCEATRI MK-5108 Prostate carcinoma (Cell Line: VCAP) [5]
PD-0325901 + Erlotinib DCKR6RN PD-0325901 Breast carcinoma (Cell Line: KPL1) [4]
PD-0325901 + Erlotinib DCZDWP3 PD-0325901 Breast carcinoma (Cell Line: OCUBM) [4]
PD-0325901 + Erlotinib DCD2M1L PD-0325901 Carcinoma (Cell Line: EFM192B) [4]
PD-0325901 + Erlotinib DC207QM PD-0325901 Carcinoma (Cell Line: MDAMB436) [4]
PD-0325901 + Erlotinib DCQNU1I PD-0325901 Colon carcinoma (Cell Line: RKO) [4]
PD-0325901 + Erlotinib DCLFMBZ PD-0325901 Rectal adenocarcinoma (Cell Line: SW837) [4]
PD-0325901 + Erlotinib DCS1OFB PD-0325901 Adenocarcinoma (Cell Line: CAOV3) [5]
PD-0325901 + Erlotinib DC4EQK5 PD-0325901 Adenocarcinoma (Cell Line: OVCAR3) [5]
PD-0325901 + Erlotinib DCNSLLU PD-0325901 Adenocarcinoma (Cell Line: A427) [5]
PD-0325901 + Erlotinib DCG03OG PD-0325901 Adenocarcinoma (Cell Line: NCIH2122) [5]
PD-0325901 + Erlotinib DCL58UE PD-0325901 Adenocarcinoma (Cell Line: NCIH23) [5]
PD-0325901 + Erlotinib DCD9KRE PD-0325901 Adenocarcinoma (Cell Line: NCIH520) [5]
PD-0325901 + Erlotinib DC64NG3 PD-0325901 Adenocarcinoma (Cell Line: COLO320DM) [5]
PD-0325901 + Erlotinib DCH3APZ PD-0325901 Adenocarcinoma (Cell Line: DLD1) [5]
PD-0325901 + Erlotinib DCAYCOB PD-0325901 Adenocarcinoma (Cell Line: HT29) [5]
PD-0325901 + Erlotinib DCI9DLZ PD-0325901 Adenocarcinoma (Cell Line: SW-620) [5]
PD-0325901 + Erlotinib DCZUCBM PD-0325901 Amelanotic melanoma (Cell Line: A2058) [5]
PD-0325901 + Erlotinib DCCE7WG PD-0325901 Germ cell tumour (Cell Line: PA1) [5]
PD-0325901 + Erlotinib DCR88YR PD-0325901 Malignant melanoma (Cell Line: A375) [5]
PD-0325901 + Erlotinib DCSDME4 PD-0325901 Malignant melanoma (Cell Line: HT144) [5]
PD-0325901 + Erlotinib DCM59RN PD-0325901 Malignant melanoma (Cell Line: RPMI7951) [5]
PD-0325901 + Erlotinib DC4WV0I PD-0325901 Malignant melanoma (Cell Line: SKMEL30) [5]
PD-0325901 + Erlotinib DC6YBKD PD-0325901 Malignant melanoma (Cell Line: UACC62) [5]
PD-0325901 + Erlotinib DCYOI3N PD-0325901 Mesothelioma (Cell Line: MSTO) [5]
PD-0325901 + Erlotinib DCW9C55 PD-0325901 Non small cell carcinoma (Cell Line: SKMES1) [5]
PD-0325901 + Erlotinib DCU8U0N PD-0325901 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
PD-0325901 + Erlotinib DCMCTUX PD-0325901 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
PD-0325901 + Erlotinib DCXKENI PD-0325901 Prostate carcinoma (Cell Line: VCAP) [5]
PMID28460551-Compound-2 + Erlotinib DCSW69F PMID28460551-Compound-2 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
PMID28460551-Compound-2 + Erlotinib DCBUGM8 PMID28460551-Compound-2 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
PMID28460551-Compound-2 + Erlotinib DCA3FKC PMID28460551-Compound-2 Breast carcinoma (Cell Line: KPL1) [4]
PMID28460551-Compound-2 + Erlotinib DC6VFZ6 PMID28460551-Compound-2 Breast carcinoma (Cell Line: OCUBM) [4]
PMID28460551-Compound-2 + Erlotinib DCZ2IWM PMID28460551-Compound-2 Carcinoma (Cell Line: OV90) [4]
PMID28460551-Compound-2 + Erlotinib DC8E2HH PMID28460551-Compound-2 Carcinoma (Cell Line: EFM192B) [4]
PMID28460551-Compound-2 + Erlotinib DC6TT3A PMID28460551-Compound-2 Carcinoma (Cell Line: MDAMB436) [4]
PMID28460551-Compound-2 + Erlotinib DCP1SOY PMID28460551-Compound-2 Colon adenocarcinoma (Cell Line: LOVO) [4]
PMID28460551-Compound-2 + Erlotinib DC1E4J8 PMID28460551-Compound-2 Colon carcinoma (Cell Line: RKO) [4]
PMID28460551-Compound-2 + Erlotinib DCFHC3U PMID28460551-Compound-2 Invasive ductal carcinoma (Cell Line: T-47D) [4]
PMID28460551-Compound-2 + Erlotinib DCBE809 PMID28460551-Compound-2 Rectal adenocarcinoma (Cell Line: SW837) [4]
PMID28460551-Compound-2 + Erlotinib DC2PVMT PMID28460551-Compound-2 Adenocarcinoma (Cell Line: OVCAR3) [5]
PMID28460551-Compound-2 + Erlotinib DCGXVT1 PMID28460551-Compound-2 Adenocarcinoma (Cell Line: CAOV3) [5]
PMID28460551-Compound-2 + Erlotinib DCDU6XE PMID28460551-Compound-2 Adenocarcinoma (Cell Line: A427) [5]
PMID28460551-Compound-2 + Erlotinib DCCBOTR PMID28460551-Compound-2 Adenocarcinoma (Cell Line: NCIH1650) [5]
PMID28460551-Compound-2 + Erlotinib DC1SFK4 PMID28460551-Compound-2 Adenocarcinoma (Cell Line: NCIH2122) [5]
PMID28460551-Compound-2 + Erlotinib DCO6MI1 PMID28460551-Compound-2 Adenocarcinoma (Cell Line: NCIH520) [5]
PMID28460551-Compound-2 + Erlotinib DCTCT8K PMID28460551-Compound-2 Adenocarcinoma (Cell Line: COLO320DM) [5]
PMID28460551-Compound-2 + Erlotinib DCMLM62 PMID28460551-Compound-2 Adenocarcinoma (Cell Line: DLD1) [5]
PMID28460551-Compound-2 + Erlotinib DCQVJCD PMID28460551-Compound-2 Adenocarcinoma (Cell Line: HT29) [5]
PMID28460551-Compound-2 + Erlotinib DCEB0PR PMID28460551-Compound-2 Adenocarcinoma (Cell Line: SW-620) [5]
PMID28460551-Compound-2 + Erlotinib DCSEJJC PMID28460551-Compound-2 Amelanotic melanoma (Cell Line: A2058) [5]
PMID28460551-Compound-2 + Erlotinib DC2ZD27 PMID28460551-Compound-2 Germ cell tumour (Cell Line: PA1) [5]
PMID28460551-Compound-2 + Erlotinib DCS4IR4 PMID28460551-Compound-2 Large cell lung carcinoma (Cell Line: NCI-H460) [5]
PMID28460551-Compound-2 + Erlotinib DCPH7R8 PMID28460551-Compound-2 Malignant melanoma (Cell Line: HT144) [5]
PMID28460551-Compound-2 + Erlotinib DCC73Y9 PMID28460551-Compound-2 Malignant melanoma (Cell Line: RPMI7951) [5]
PMID28460551-Compound-2 + Erlotinib DCQNOYI PMID28460551-Compound-2 Malignant melanoma (Cell Line: SKMEL30) [5]
PMID28460551-Compound-2 + Erlotinib DCTKTI1 PMID28460551-Compound-2 Malignant melanoma (Cell Line: UACC62) [5]
PMID28460551-Compound-2 + Erlotinib DC35VQ9 PMID28460551-Compound-2 Malignant melanoma (Cell Line: A375) [5]
PMID28460551-Compound-2 + Erlotinib DCGXAW3 PMID28460551-Compound-2 Mesothelioma (Cell Line: MSTO) [5]
PMID28460551-Compound-2 + Erlotinib DC03OBE PMID28460551-Compound-2 Non small cell carcinoma (Cell Line: SKMES1) [5]
PMID28460551-Compound-2 + Erlotinib DCCMFAW PMID28460551-Compound-2 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
PMID28460551-Compound-2 + Erlotinib DCU4UVO PMID28460551-Compound-2 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
PMID28460551-Compound-2 + Erlotinib DC4QS65 PMID28460551-Compound-2 Prostate carcinoma (Cell Line: LNCAP) [5]
PMID28460551-Compound-2 + Erlotinib DC4WF60 PMID28460551-Compound-2 Prostate carcinoma (Cell Line: VCAP) [5]
SCH 727965 + Erlotinib DCOO2Y4 SCH 727965 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
SCH 727965 + Erlotinib DC06VGB SCH 727965 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
SCH 727965 + Erlotinib DC93LHY SCH 727965 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
SCH 727965 + Erlotinib DCEDSJE SCH 727965 Breast carcinoma (Cell Line: KPL1) [4]
SCH 727965 + Erlotinib DCUBHQ4 SCH 727965 Breast carcinoma (Cell Line: OCUBM) [4]
SCH 727965 + Erlotinib DCFGRDD SCH 727965 Carcinoma (Cell Line: OV90) [4]
SCH 727965 + Erlotinib DCR1TJX SCH 727965 Carcinoma (Cell Line: EFM192B) [4]
SCH 727965 + Erlotinib DCTVIH3 SCH 727965 Carcinoma (Cell Line: MDAMB436) [4]
SCH 727965 + Erlotinib DCA0IUH SCH 727965 Colon adenocarcinoma (Cell Line: LOVO) [4]
SCH 727965 + Erlotinib DC17L6R SCH 727965 Invasive ductal carcinoma (Cell Line: T-47D) [4]
SCH 727965 + Erlotinib DCKS52X SCH 727965 Rectal adenocarcinoma (Cell Line: SW837) [4]
SCH 727965 + Erlotinib DCBGK5Y SCH 727965 Adenocarcinoma (Cell Line: CAOV3) [5]
SCH 727965 + Erlotinib DCVT3OI SCH 727965 Adenocarcinoma (Cell Line: OVCAR3) [5]
SCH 727965 + Erlotinib DCK04LM SCH 727965 Adenocarcinoma (Cell Line: A427) [5]
SCH 727965 + Erlotinib DCYLYV6 SCH 727965 Adenocarcinoma (Cell Line: NCIH1650) [5]
SCH 727965 + Erlotinib DC9TDN7 SCH 727965 Adenocarcinoma (Cell Line: NCIH23) [5]
SCH 727965 + Erlotinib DCVUDQ8 SCH 727965 Adenocarcinoma (Cell Line: NCIH520) [5]
SCH 727965 + Erlotinib DC7WFAI SCH 727965 Adenocarcinoma (Cell Line: COLO320DM) [5]
SCH 727965 + Erlotinib DCLRN0Z SCH 727965 Adenocarcinoma (Cell Line: DLD1) [5]
SCH 727965 + Erlotinib DC98ZPQ SCH 727965 Adenocarcinoma (Cell Line: HT29) [5]
SCH 727965 + Erlotinib DCX2GQ8 SCH 727965 Adenocarcinoma (Cell Line: SW-620) [5]
SCH 727965 + Erlotinib DC33XGD SCH 727965 Amelanotic melanoma (Cell Line: A2058) [5]
SCH 727965 + Erlotinib DCAMBJA SCH 727965 Germ cell tumour (Cell Line: PA1) [5]
SCH 727965 + Erlotinib DCZPDQ3 SCH 727965 Malignant melanoma (Cell Line: A375) [5]
SCH 727965 + Erlotinib DC36TQ7 SCH 727965 Malignant melanoma (Cell Line: HT144) [5]
SCH 727965 + Erlotinib DCHT28T SCH 727965 Malignant melanoma (Cell Line: RPMI7951) [5]
SCH 727965 + Erlotinib DC2RR4R SCH 727965 Malignant melanoma (Cell Line: SKMEL30) [5]
SCH 727965 + Erlotinib DC4J01B SCH 727965 Malignant melanoma (Cell Line: UACC62) [5]
SCH 727965 + Erlotinib DC2M3XJ SCH 727965 Non small cell carcinoma (Cell Line: SKMES1) [5]
SCH 727965 + Erlotinib DCGASXP SCH 727965 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
SCH 727965 + Erlotinib DCGPPPC SCH 727965 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
SCH 727965 + Erlotinib DCHQO4B SCH 727965 Prostate carcinoma (Cell Line: LNCAP) [5]
SCH 727965 + Erlotinib DCHM9M2 SCH 727965 Prostate carcinoma (Cell Line: VCAP) [5]
Taxol + Erlotinib DCX0DJT Taxol Breast carcinoma (Cell Line: OCUBM) [4]
Taxol + Erlotinib DCRGN7E Taxol Carcinoma (Cell Line: EFM192B) [4]
Taxol + Erlotinib DC9LWZ4 Taxol Adenocarcinoma (Cell Line: CAOV3) [5]
Taxol + Erlotinib DCJE5QM Taxol Adenocarcinoma (Cell Line: OVCAR3) [5]
Taxol + Erlotinib DCH27YA Taxol Adenocarcinoma (Cell Line: NCIH2122) [5]
Taxol + Erlotinib DC5VT3P Taxol Adenocarcinoma (Cell Line: NCIH520) [5]
Taxol + Erlotinib DCCVPFR Taxol Adenocarcinoma (Cell Line: COLO320DM) [5]
Taxol + Erlotinib DCIH7G3 Taxol Adenocarcinoma (Cell Line: DLD1) [5]
Taxol + Erlotinib DCUDDK0 Taxol Adenocarcinoma (Cell Line: HT29) [5]
Taxol + Erlotinib DC01B5H Taxol Adenocarcinoma (Cell Line: SW-620) [5]
Taxol + Erlotinib DCX8RE7 Taxol Germ cell tumour (Cell Line: PA1) [5]
Taxol + Erlotinib DCF7ZHQ Taxol Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Taxol + Erlotinib DCJA82X Taxol Malignant melanoma (Cell Line: A375) [5]
Taxol + Erlotinib DCUV740 Taxol Malignant melanoma (Cell Line: HT144) [5]
Taxol + Erlotinib DCCK40Q Taxol Malignant melanoma (Cell Line: RPMI7951) [5]
Taxol + Erlotinib DCAZ60S Taxol Malignant melanoma (Cell Line: SKMEL30) [5]
Taxol + Erlotinib DCG0R6M Taxol Malignant melanoma (Cell Line: UACC62) [5]
Taxol + Erlotinib DCPWGK0 Taxol Mesothelioma (Cell Line: MSTO) [5]
Taxol + Erlotinib DC8EXCJ Taxol Non small cell carcinoma (Cell Line: SKMES1) [5]
Taxol + Erlotinib DCOGBJH Taxol Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Taxol + Erlotinib DCH2AY4 Taxol Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Topotecan + Erlotinib DCSYELD Topotecan Breast carcinoma (Cell Line: KPL1) [4]
Topotecan + Erlotinib DCRBDG0 Topotecan Breast carcinoma (Cell Line: OCUBM) [4]
Topotecan + Erlotinib DCRZ96R Topotecan Carcinoma (Cell Line: EFM192B) [4]
Topotecan + Erlotinib DCEGDPR Topotecan Carcinoma (Cell Line: MDAMB436) [4]
Topotecan + Erlotinib DCL6352 Topotecan Colon adenocarcinoma (Cell Line: LOVO) [4]
Topotecan + Erlotinib DCGE7O7 Topotecan Colon carcinoma (Cell Line: RKO) [4]
Topotecan + Erlotinib DC8O778 Topotecan Adenocarcinoma (Cell Line: CAOV3) [5]
Topotecan + Erlotinib DCGBFH4 Topotecan Adenocarcinoma (Cell Line: OVCAR3) [5]
Topotecan + Erlotinib DCSMBDL Topotecan Adenocarcinoma (Cell Line: A427) [5]
Topotecan + Erlotinib DCZPFC0 Topotecan Adenocarcinoma (Cell Line: NCIH2122) [5]
Topotecan + Erlotinib DCF8G91 Topotecan Adenocarcinoma (Cell Line: NCIH23) [5]
Topotecan + Erlotinib DC0FIVH Topotecan Adenocarcinoma (Cell Line: NCIH520) [5]
Topotecan + Erlotinib DCPEV27 Topotecan Adenocarcinoma (Cell Line: COLO320DM) [5]
Topotecan + Erlotinib DC8CQPP Topotecan Adenocarcinoma (Cell Line: DLD1) [5]
Topotecan + Erlotinib DC29TC4 Topotecan Adenocarcinoma (Cell Line: HCT116) [5]
Topotecan + Erlotinib DCFNQLC Topotecan Adenocarcinoma (Cell Line: HT29) [5]
Topotecan + Erlotinib DCDWI6U Topotecan Adenocarcinoma (Cell Line: SW-620) [5]
Topotecan + Erlotinib DCI1ZUN Topotecan Amelanotic melanoma (Cell Line: A2058) [5]
Topotecan + Erlotinib DCO31CG Topotecan Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [5]
Topotecan + Erlotinib DC8DUJ4 Topotecan Germ cell tumour (Cell Line: PA1) [5]
Topotecan + Erlotinib DCX3PDX Topotecan Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Topotecan + Erlotinib DCLCASU Topotecan Malignant melanoma (Cell Line: A375) [5]
Topotecan + Erlotinib DC54PVX Topotecan Malignant melanoma (Cell Line: HT144) [5]
Topotecan + Erlotinib DC6JX2H Topotecan Malignant melanoma (Cell Line: RPMI7951) [5]
Topotecan + Erlotinib DCJKQCL Topotecan Malignant melanoma (Cell Line: SKMEL30) [5]
Topotecan + Erlotinib DCDM74B Topotecan Malignant melanoma (Cell Line: UACC62) [5]
Topotecan + Erlotinib DCOCYTO Topotecan Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Topotecan + Erlotinib DC0D2P3 Topotecan Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Topotecan + Erlotinib DCZVHNJ Topotecan Prostate carcinoma (Cell Line: VCAP) [5]
Tosyl-l-arginine methyl ester + Erlotinib DCUU9QF Tosyl-l-arginine methyl ester Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [3]
Vinblastine + Erlotinib DCW2GRA Vinblastine Adenocarcinoma (Cell Line: CAOV3) [3]
Vinblastine + Erlotinib DC7G2ZT Vinblastine Adenocarcinoma (Cell Line: OVCAR3) [3]
Vinblastine + Erlotinib DCZBLQV Vinblastine Adenocarcinoma (Cell Line: NCIH2122) [3]
Vinblastine + Erlotinib DC5PSCC Vinblastine Adenocarcinoma (Cell Line: NCIH23) [3]
Vinblastine + Erlotinib DCAZPFL Vinblastine Adenocarcinoma (Cell Line: NCIH520) [3]
Vinblastine + Erlotinib DCNCXJ5 Vinblastine Adenocarcinoma (Cell Line: COLO320DM) [3]
Vinblastine + Erlotinib DCGYEBI Vinblastine Adenocarcinoma (Cell Line: DLD1) [3]
Vinblastine + Erlotinib DC20J6W Vinblastine Adenocarcinoma (Cell Line: HT29) [3]
Vinblastine + Erlotinib DCF9XRI Vinblastine Amelanotic melanoma (Cell Line: A2058) [3]
Vinblastine + Erlotinib DCTQ92E Vinblastine Germ cell tumour (Cell Line: PA1) [3]
Vinblastine + Erlotinib DC76Y9J Vinblastine Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Vinblastine + Erlotinib DC4FDC7 Vinblastine Malignant melanoma (Cell Line: A375) [3]
Vinblastine + Erlotinib DCHW9OX Vinblastine Malignant melanoma (Cell Line: HT144) [3]
Vinblastine + Erlotinib DCRKMXS Vinblastine Malignant melanoma (Cell Line: RPMI7951) [3]
Vinblastine + Erlotinib DCZQ1GF Vinblastine Malignant melanoma (Cell Line: SKMEL30) [3]
Vinblastine + Erlotinib DC9TKEZ Vinblastine Malignant melanoma (Cell Line: UACC62) [3]
Vinblastine + Erlotinib DCYJQ3Q Vinblastine Mesothelioma (Cell Line: MSTO) [3]
Vinblastine + Erlotinib DC1IRZJ Vinblastine Non small cell carcinoma (Cell Line: SKMES1) [3]
Vinblastine + Erlotinib DC7G85P Vinblastine Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
Vinblastine + Erlotinib DC1P3J5 Vinblastine Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Vinblastine + Erlotinib DCIVCDH Vinblastine Prostate carcinoma (Cell Line: LNCAP) [3]
Vinblastine + Erlotinib DCMPB62 Vinblastine Prostate carcinoma (Cell Line: VCAP) [3]
Vinblastine + Erlotinib DC8CMK9 Vinblastine Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Vinblastine + Erlotinib DCI13R3 Vinblastine Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Vinblastine + Erlotinib DCDF3KR Vinblastine Breast carcinoma (Cell Line: KPL1) [4]
Vinblastine + Erlotinib DCJU62R Vinblastine Breast carcinoma (Cell Line: OCUBM) [4]
Vinblastine + Erlotinib DCQW2AJ Vinblastine Carcinoma (Cell Line: OV90) [4]
Vinblastine + Erlotinib DC9S1R1 Vinblastine Carcinoma (Cell Line: MDAMB436) [4]
Vinblastine + Erlotinib DCU8NRA Vinblastine Colon adenocarcinoma (Cell Line: LOVO) [4]
Vinblastine + Erlotinib DCBRNJ0 Vinblastine Colon carcinoma (Cell Line: RKO) [4]
Vinblastine + Erlotinib DC7EG8P Vinblastine Invasive ductal carcinoma (Cell Line: T-47D) [4]
Vinblastine + Erlotinib DCYKB6V Vinblastine Rectal adenocarcinoma (Cell Line: SW837) [4]
Vinorelbine + Erlotinib DCPRDRI Vinorelbine Breast carcinoma (Cell Line: OCUBM) [4]
Vinorelbine + Erlotinib DCSGBQQ Vinorelbine Carcinoma (Cell Line: OV90) [4]
Vinorelbine + Erlotinib DC5YZF4 Vinorelbine Carcinoma (Cell Line: EFM192B) [4]
Vinorelbine + Erlotinib DC3OJVK Vinorelbine Carcinoma (Cell Line: MDAMB436) [4]
Vinorelbine + Erlotinib DCBQIJI Vinorelbine Colon adenocarcinoma (Cell Line: LOVO) [4]
Vinorelbine + Erlotinib DCWQ4ZO Vinorelbine Rectal adenocarcinoma (Cell Line: SW837) [4]
Vinorelbine + Erlotinib DCTPRB4 Vinorelbine Adenocarcinoma (Cell Line: OVCAR3) [5]
Vinorelbine + Erlotinib DC58OAH Vinorelbine Adenocarcinoma (Cell Line: A427) [5]
Vinorelbine + Erlotinib DCENV0X Vinorelbine Adenocarcinoma (Cell Line: NCIH2122) [5]
Vinorelbine + Erlotinib DC2950Q Vinorelbine Adenocarcinoma (Cell Line: NCIH520) [5]
Vinorelbine + Erlotinib DCH8S40 Vinorelbine Adenocarcinoma (Cell Line: COLO320DM) [5]
Vinorelbine + Erlotinib DC0AD7U Vinorelbine Adenocarcinoma (Cell Line: DLD1) [5]
Vinorelbine + Erlotinib DCOHH5L Vinorelbine Adenocarcinoma (Cell Line: HT29) [5]
Vinorelbine + Erlotinib DCWKBQR Vinorelbine Adenocarcinoma (Cell Line: SW-620) [5]
Vinorelbine + Erlotinib DCY3PST Vinorelbine Germ cell tumour (Cell Line: PA1) [5]
Vinorelbine + Erlotinib DCB384L Vinorelbine Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Vinorelbine + Erlotinib DCPGC94 Vinorelbine Malignant melanoma (Cell Line: A375) [5]
Vinorelbine + Erlotinib DCJQSYV Vinorelbine Malignant melanoma (Cell Line: HT144) [5]
Vinorelbine + Erlotinib DC3A7FA Vinorelbine Malignant melanoma (Cell Line: SKMEL30) [5]
Vinorelbine + Erlotinib DCZU8TS Vinorelbine Malignant melanoma (Cell Line: UACC62) [5]
Vinorelbine + Erlotinib DCZWOCB Vinorelbine Non small cell carcinoma (Cell Line: SKMES1) [5]
Vinorelbine + Erlotinib DCY63SQ Vinorelbine Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Vinorelbine + Erlotinib DC4ZE43 Vinorelbine Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Vinorelbine + Erlotinib DCQ5QF0 Vinorelbine Prostate carcinoma (Cell Line: LNCAP) [5]
Vinorelbine + Erlotinib DC3DWQM Vinorelbine Prostate carcinoma (Cell Line: VCAP) [5]
------------------------------------------------------------------------------------
⏷ Show the Full List of 809 DrugCom(s)
82 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Arry-162 + Erlotinib DCLMQ1W Arry-162 Lung Cancer [6]
Captopril + Erlotinib DC255BE Captopril Carcinoma, Large Cell [7]
Celecoxib + Erlotinib DC1M6Z2 Celecoxib Recurrent Non-small Cell Lung Cancer [8]
Crizotinib + Erlotinib DCFQJ4P Crizotinib Non-Small Cell Lung Cancer [9]
Doxycycline + Erlotinib DC2X23P Doxycycline Non-Small Cell Lung Cancer [10]
Enzastaurin + Erlotinib DCNTHLC Enzastaurin Non-Small Cell Lung Cancer [11]
Erlotinib + Etoposide DCBAO0J Etoposide Recurrent Childhood Brain Tumor [12]
Erlotinib + Docetaxel DCDPJ7J Docetaxel Lung Cancer [13]
Erlotinib + Pemetrexed DC0OGCP Pemetrexed Histological or Cytological Diagnosis of Locally Advanced or Metastatic NSCLC of Nonsquamous Histology and Not Amenable to Curative Therapy. [14]
Erlotinib + Docetaxel DC1W6LW Docetaxel Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma [15]
Erlotinib + Pazopanib DC2MGUV Pazopanib Lung Cancer, Non-Small Cell [16]
Erlotinib + Metronidazole DC3P67M Metronidazole Non-Squamous Non-Small Cell Lung Cancer [17]
Erlotinib + Tasisulam DC4YUJT Tasisulam Advanced Solid Tumors [18]
Erlotinib + Bexarotene DC6QIZI Bexarotene Lung Cancer [19]
Erlotinib + Cabozantinib DC6Z0ZX Cabozantinib Carcinoma, Non-Small-Cell Lung [20]
Erlotinib + SNDX-275 DC6ZL1I SNDX-275 Non-Small-Cell Lung Carcinoma [21]
Erlotinib + Hydroxychloroquine DC8E5ST Hydroxychloroquine Non-small Cell Lung Cancer [22]
Erlotinib + Topotecan DC9L4H9 Topotecan Metastatic Solid Tumor [23]
Erlotinib + Vinflunine DCB80B5 Vinflunine Unspecified Adult Solid Tumor, Protocol Specific [24]
Erlotinib + Vorinostat DCEPOR6 Vorinostat Carcinoma, Non-Small-Cell Lung [25]
Erlotinib + Dasatinib DCFLAUJ Dasatinib Lung Cancer [26]
Erlotinib + Docetaxel DCGAKWQ Docetaxel Recurrent Salivary Gland Cancer [27]
Erlotinib + Pemetrexed DCGQLKX Pemetrexed Lung Cancer [28]
Erlotinib + JM216 DCGVQ8I JM216 Lung Cancer [29]
Erlotinib + Temsirolimus DCHJAAP Temsirolimus Adult Anaplastic Astrocytoma [30]
Erlotinib + Capecitabine DCHPW08 Capecitabine Pancreatic Cancer [31]
Erlotinib + Fusidic acid DCIHJX7 Fusidic acid Non-Small Cell Lung Cancer [32]
Erlotinib + Alectinib DCJVU80 Alectinib Non-Small-Cell Lung Carcinoma [33]
Erlotinib + Temozolomide DCKNYM9 Temozolomide CNS Tumor, Adult [34]
Erlotinib + Xl147 DCL75SK Xl147 Cancer [35]
Erlotinib + Irinotecan DCMDZO3 Irinotecan Colorectal Cancer [36]
Erlotinib + Tivantinib DCOBMN1 Tivantinib Non Small Cell Lung Cancer [37]
Erlotinib + Tivozanib DCPSAAG Tivozanib Non-small Cell Lung Cancer [38]
Erlotinib + Anastrozole DCPTGI4 Anastrozole Solid Tumors [39]
Erlotinib + Paclitaxel DCRZOWJ Paclitaxel Unspecified Adult Solid Tumor, Protocol Specific [40]
Erlotinib + Temozolomide DCTAY2B Temozolomide Adult Giant Cell Glioblastoma [41]
Erlotinib + Pemetrexed DCTG9PO Pemetrexed Non-Small-Cell Lung Cancer [42]
Erlotinib + Metformin DCTNWMD Metformin Breast Cancer [43]
Erlotinib + Vinorelbine DCYF1JE Vinorelbine Non-Small Cell Lung Cancer [44]
Erlotinib + ABT-263 DCZVW5N ABT-263 Solid Tumors [45]
Erlotinib + Bevacizumab DCSEFCM Bevacizumab Metastatic colorectal cancer; Non-small-cell lung cancer; Hypopharyngeal squamous cell carcinoma; Hepatocellular carcinoma [46]
Erlotinib + Carboplatin DCGMKYS Carboplatin Adenocarcinoma of the Lung [47]
Erlotinib + Axitinib DC7G46O Axitinib Neoplasms [48]
Erlotinib + Capmatinib DCBLDLO Capmatinib Recurrent Non-small Cell Lung Cancer [49]
Erlotinib + Gilteritinib DCI05IV Gilteritinib Non-Small-Cell Lung Cancer [50]
Erlotinib + Theophylline DCLIF0U Theophylline Non-small Cell Lung Cancer [51]
Erlotinib + BGB-324 DCNCRCV BGB-324 Non-Small Cell Lung Cancer [52]
Erlotinib + Momelotinib DCWDWWK Momelotinib EGFR Mutated EGFR TKI Naive Metastatic NSCLC [53]
Erythromycin + Erlotinib DC9H7WN Erythromycin Non-Small Cell Lung Cancer [32]
Everolimus + Erlotinib DCJHBPT Everolimus Unspecified Adult Solid Tumor, Protocol Specific [54]
Fulvestrant + Erlotinib DCCGXQX Fulvestrant Stage IV Lung Cancer [55]
Fulvestrant + Erlotinib DCQZ7IC Fulvestrant Lung Cancer [56]
Gefitinib + Erlotinib DCBK20C Gefitinib Non-squamous, Non-Small Cell Lung Cancer [57]
Gemcitabine + Erlotinib DCDDX5Y Gemcitabine Pancreatic Cancer [58]
Gemcitabine + Erlotinib DCSTD1Q Gemcitabine Metastatic Pancreatic Carcinoma [59]
Indibulin + Erlotinib DCKV7I3 Indibulin Advanced Solid Tumors [60]
Isotretinoin + Erlotinib DCINDQI Isotretinoin Adult Anaplastic Astrocytoma [61]
Lenvatinib + Erlotinib DCJZXID Lenvatinib Neoplasms [48]
Pacritinib + Erlotinib DCJYKEM Pacritinib Non-Small Cell Lung Cancer [62]
Panobinostat + Erlotinib DCPN5FQ Panobinostat Lung Cancer [63]
Ruxolitinib + Erlotinib DC8UIKF Ruxolitinib Lung Cancer [64]
Selumetinib + Erlotinib DCGZUC6 Selumetinib Breast Cancer [65]
Sulindac + Erlotinib DC4Q7LG Sulindac Squamous Cell Carcinoma of the Head and Neck (SCCHN) [66]
Sulindac + Erlotinib DCF9DDX Sulindac Adenomatous Polyposis Coli [67]
Sunitinib + Erlotinib DC0O0KQ Sunitinib Carcinoma, Non-Small-Cell Lung [68]
Trametinib + Erlotinib DCADB8C Trametinib Cancer [69]
Erlotinib + Docetaxel DC0K3P2 Docetaxel Non Small Cell Lung Cancer [70]
Erlotinib + Carboplatin DCRJL0M Carboplatin Lung Cancer [71]
Erlotinib + Carboplatin DCZQ27L Carboplatin Recurrent Non-small Cell Lung Cancer [72]
Erlotinib + Cabozantinib DC2VT6E Cabozantinib Pancreatic Adenocarcinoma Metastatic [73]
Erlotinib + Afatinib DC9DY4O Afatinib Lung Cancer [74]
Erlotinib + Dasatinib DCPFSHH Dasatinib Diffuse Intrinsic Pontine Glioma [75]
Erlotinib + INCB039110 DCPPCPS INCB039110 Solid Tumors and Hematologic Malignancy [76]
Erlotinib + XL880 DCU3AFM XL880 Cancer [77]
Everolimus + Erlotinib DCEOUMC Everolimus Diffuse Intrinsic Pontine Glioma [75]
Gefitinib + Erlotinib DC7ZR22 Gefitinib Non-small Cell Lung Cancer [78]
Gemcitabine + Erlotinib DC3AA12 Gemcitabine Pancreatic Adenocarcinoma [79]
Gemcitabine + Erlotinib DCAEE26 Gemcitabine Pancreatic Cancer [80]
Gemcitabine + Erlotinib DCSULYL Gemcitabine Locally Advanced Pancreatic Cancer [81]
Erlotinib + Docetaxel DCCQEC5 Docetaxel Non-Squamous Non-Small Cell Lung Cancer [82]
Gefitinib + Erlotinib DC8A9UP Gefitinib Non-small Cell Lung Cancer (NSCLC) [83]
Gemcitabine + Erlotinib DCH3LJR Gemcitabine Non - Small Cell Lung Cancer NSCLC [84]
------------------------------------------------------------------------------------
⏷ Show the Full List of 82 DrugCom(s)

References

1 Erlotinib FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4920).
3 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
4 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
5 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
6 ClinicalTrials.gov (NCT01859026) A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation
7 ClinicalTrials.gov (NCT00673049) Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer
8 ClinicalTrials.gov (NCT00062101) Erlotinib and Celecoxib in Treating Patients With Stage IIIB or Stage IV Recurrent Non-Small Cell Lung Cancer
9 ClinicalTrials.gov (NCT00965731) Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer
10 ClinicalTrials.gov (NCT00531934) A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer.
11 ClinicalTrials.gov (NCT00452413) A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer
12 ClinicalTrials.gov (NCT02015728) Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors
13 ClinicalTrials.gov (NCT00660816) Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
14 ClinicalTrials.gov (NCT00447057) Study of Pemetrexed Versus Pemetrexed Plus Erlotinib as Treatment of Nonsquamous Non-Small Cell Lung Cancer (NSCLC)
15 ClinicalTrials.gov (NCT00049283) Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer
16 ClinicalTrials.gov (NCT00619424) A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid Tumors
17 ClinicalTrials.gov (NCT00642473) A Study of Metronidazole Cream in the Prevention and Treatment of Tarceva (Erlotinib)-Associated Rash
18 ClinicalTrials.gov (NCT01284335) A Safety Study in Participants With Advanced Solid Tumors
19 ClinicalTrials.gov (NCT00411632) BATTLE Program: Tarceva and Targretin in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
20 ClinicalTrials.gov (NCT00596648) A Study of XL184 (Cabozantinib) With or Without Erlotinib in Adults With Non-Small Cell Lung Cancer
21 ClinicalTrials.gov (NCT00602030) Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC
22 ClinicalTrials.gov (NCT00977470) Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations
23 ClinicalTrials.gov (NCT00611468) Phase I, Dosage-finding and PK Study of IV Topotecan and Erlotinib With Refractory Solid Tumors
24 ClinicalTrials.gov (NCT00320073) Vinflunine and Erlotinib or Pemetrexed in Treating Patients With Unresectable or Metastatic Solid Tumors
25 ClinicalTrials.gov (NCT00251589) A Phase I/II Clinical Trial of Vorinostat in Combination With Erlotinib for Patients With Relapsed/Refractory Non-Small-Cell Lung Cancer (0683-025)
26 ClinicalTrials.gov (NCT00826449) Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)
27 ClinicalTrials.gov (NCT00055770) Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer
28 ClinicalTrials.gov (NCT00387322) Pemetrexed Disodium and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
29 ClinicalTrials.gov (NCT00370383) A Study Comparing Sequential Satraplatin & Erlotinib to Erlotinib in Unresectable Stage 3/4 Non-small-cell Lung Cancer (NSCLC)
30 ClinicalTrials.gov (NCT00112736) Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma
31 ClinicalTrials.gov (NCT00440167) Capecitabine/Erlotinib Followed of Gemcitabine Versus Gemcitabine/Erlotinib Followed of Capecitabine
32 ClinicalTrials.gov (NCT00718315) A Study of Verutex (Fusidic Acid), Eritex (Erythromycin) and Fisiogel in the Management of Tarceva-Associated Rash.
33 ClinicalTrials.gov (NCT01801111) A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment
34 ClinicalTrials.gov (NCT00274833) Radiation Therapy, Temozolomide, and Erlotinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
35 ClinicalTrials.gov (NCT00692640) Safety Study of XL147 (SAR245408) in Combination With Erlotinib in Adults With Solid Tumors
36 ClinicalTrials.gov (NCT00940316) Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer
37 ClinicalTrials.gov (NCT00777309) A Randomized Phase 2 Study of Erlotinib + ARQ 197 Versus Erlotinib + Placebo in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
38 ClinicalTrials.gov (NCT01728181) A Phase I/II Study of Tivozanib and Erlotinib as Initial Treatment for Metastatic Non-small Cell Lung Cancer Assigned by VeriStrat Serum Proteomic Evaluation
39 ClinicalTrials.gov (NCT01197170) Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
40 ClinicalTrials.gov (NCT00042809) Erlotinib, Trastuzumab, and Paclitaxel in Treating Patients With Advanced Solid Tumors
41 ClinicalTrials.gov (NCT00039494) Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors
42 ClinicalTrials.gov (NCT00550173) A Study for Non-Smoker Patients With Nonsquamous Non-Small Cell Lung Cancer
43 ClinicalTrials.gov (NCT01650506) Study of Erlotinib and Metformin in Triple Negative Breast Cancer
44 ClinicalTrials.gov (NCT00702182) Study of Oral Vinorelbine and Erlotinib in Non-Small Cell Lung Cancer
45 ClinicalTrials.gov (NCT01009073) A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects
46 FDA Drug Development and Drug Interactions
47 ClinicalTrials.gov (NCT00042835) Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer
48 ClinicalTrials.gov (NCT06161558) Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors
49 ClinicalTrials.gov (NCT01911507) INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer
50 ClinicalTrials.gov (NCT02495233) A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)
51 ClinicalTrials.gov (NCT02080078) A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline
52 ClinicalTrials.gov (NCT02424617) A Study of BGB324(Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer
53 ClinicalTrials.gov (NCT02206763) Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)
54 ClinicalTrials.gov (NCT00276575) Bevacizumab, Everolimus, and Erlotinib in Treating Patients With Advanced Solid Tumors
55 ClinicalTrials.gov (NCT01556191) Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFR
56 ClinicalTrials.gov (NCT00100854) Erlotinib With or Without Fulvestrant in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
57 ClinicalTrials.gov (NCT04179890) The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib
58 ClinicalTrials.gov (NCT00461708) A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship Between Skin Toxicity and Survival
59 ClinicalTrials.gov (NCT00480584) A Phase I Trial of Capecitabine in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic Cancer
60 ClinicalTrials.gov (NCT00591383) Phase I Study of Indibulin in Combination With Erlotinib in Advanced Solid Tumors
61 ClinicalTrials.gov (NCT01103375) Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma
62 ClinicalTrials.gov (NCT02342353) Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI)
63 ClinicalTrials.gov (NCT00738751) Phase I Study of LBH589 & Erlotinib for Advanced Aerodigestive Tract Cancers
64 ClinicalTrials.gov (NCT02155465) Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib
65 ClinicalTrials.gov (NCT00600496) A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
66 ClinicalTrials.gov (NCT00392665) Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck
67 ClinicalTrials.gov (NCT01187901) A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients
68 ClinicalTrials.gov (NCT00265317) A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 (Sunitinib) Is Better Than Erlotinib Alone
69 ClinicalTrials.gov (NCT01192165) Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
70 ClinicalTrials.gov (NCT02037997) Safety and Effectiveness Study of Chemotherapy in Combination With Erlotinib,or Sequential Erlotinib for Treatment in Patients With NSCLC
71 ClinicalTrials.gov (NCT01344824) Carboplatin, Pemetrexed Disodium, and Bevacizumab for Patients With Stage III or IV Non-Small Cell Lung Cancer Who Are Light/Never Smokers
72 ClinicalTrials.gov (NCT00976677) Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
73 ClinicalTrials.gov (NCT03213626) Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic Adenocarcinoma
74 ClinicalTrials.gov (NCT02625168) Afatinib vs Erlotinib as 2nd TKI After Failure to 1st TKI and Chemotherapy for Metastatic NSCLC
75 ClinicalTrials.gov (NCT02233049) Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication
76 ClinicalTrials.gov (NCT02355431) Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations
77 ClinicalTrials.gov (NCT02034097) A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung Cancer
78 ClinicalTrials.gov (NCT03653546) First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases
79 ClinicalTrials.gov (NCT00728000) Phase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic Adenocarcinoma
80 ClinicalTrials.gov (NCT00564720) Gemcitabine Plus Erlotinib Versus Erlotinib Plus Gemcitabine Plus Oxaliplatin, in Pancreatic Cancer
81 ClinicalTrials.gov (NCT01210911) Metformin Combined With Chemotherapy for Pancreatic Cancer
82 ClinicalTrials.gov (NCT01351415) A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)
83 ClinicalTrials.gov (NCT02588261) A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations
84 ClinicalTrials.gov (NCT02352948) A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer